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A B S T R A C T
High throughput sequencing has established itself as a standard tool in a wide array
of biological investigations. This data source is rich in complexity and has the potential
to uncover many aspects of the biological system of interest. Concurrently, as the di-
mensionality of available data increases, the scope of biological questions one may ask
become increasingly complex and require tailored statistical approaches to effectively
address these issues. This thesis explores three distinct biological systems in which
high throughput sequencing data is utilised. These investigations vary in research
area, organism, number of sequencing platforms integrated, number of separate data-
sets integrated, and the presence of structure such as matched samples; showcasing
the immense variety of study designs and the need for tailored statistical approaches.
We make use of these data sources as well as other sources of information such as
networks.
First, we elucidate allelic imbalance in a cohort of livestock animals. We propose a
method to characterise allelic imbalance from RNA Sequencing data including strin-
gent filtering criteria and a count based likelihood ratio test. This work identified genes
of particular importance in livestock genomics such as those related to energy use.
Second, we outline a novel methodology for identifying highly expressed genes and
cells for single cell RNA Sequencing data. We utilise nine publicly available mouse
neuron datasets, three of which are specifically related to olfactory sensory neurons.
We derive a gamma-normal mixture model to identify lowly and highly expressed
components, and use this to identify novel markers for olfactory sensory neuron ma-
turity. In addition we estimate single cell networks and find that mature olfactory sens-
ory neuron single cell networks are more centralised than immature olfactory sensory
neuron single cell networks, consistent with recent findings in the literature.
Third, in the context of exploratory study of multiple human cancers; we develop
two novel frameworks for relating information from Whole Exome DNA Sequencing
and RNA Sequencing data when i) samples are matched between platforms and when
ii) samples are not necessary matched between platforms. In the latter case, we relate
functional driver gene scores from identified somatic mutations to network correlation
disturbance between groups of cancer patients using a permutation testing framework,
identifying potential candidate genes for targeted cancer therapies. In the former case,
we estimate directed mutation-expression networks for each cancer using linear mod-
els, providing a useful exploratory tool for identifying novel regulatory relationships
potentially leading to improved global understanding of cancers and discovery of novel
treatments. The opportunity for exploration is enhanced by interactive visualisation of
estimated cancer mutation-expression networks via the R Shiny application PACMEN:
PAn Cancer Mutation Expression Networks, aiding in expediting efficient exploration
of these complex datasets.
The development of novel statistical approaches to questions specific to biological
systems of interest is becoming more valuable as we move towards tackling increas-
ingly complex problems. This thesis demonstrates the importance of tailored statistical
approaches to further understanding across many biological systems.
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The advent of high throughput sequencing (HTS) over the last decade has revolu-
tionised molecular biological and medical research. Insights from data stemming from
these technologies have unveiled the enormous complexity in biological systems, lead-
ing to many more biological questions to be interrogated. Soon after the successful
sequencing of the first human genome in 2003 (Human Genome Sequencing Consor-
tium, 2004) and consequently the successful sequencing of the human genome using
HTS in 2007 (Wheeler et al., 2008), it became readily apparent that knowledge of the
genetic sequence is simply not enough to understand human biology. Despite obtain-
ing the blueprint of human life, the human DNA genetic sequence, no further clues
towards understanding biology and disease were available without taking into account
the dynamic nature of the biological system in which the blueprint exists.
Currently, we are in a unique position to dissect the complexity of biological systems,
due to not only the increased volume of HTS datasets, but increase in the breadth of
specific HTS data types. Interdisciplinary statisticians are in the unique position to
understand the biological questions of interest and develop customised approaches
to effectively build models and address questions using these new data. Not only do
typical datasets from HTS studies contain many variables, but a vast and complex inter-
connectedness exists between these variables. Analytical approaches increasingly need
to take into account the relationships between variables, potentially by considering
information sources on these interdependencies.
Parallel to the generation of datasets using HTS technologies are the curation of bio-
logical databases. These databases can come in the form of networks, such as protein-
protein interaction (PPI) networks. These represent concerted efforts to unpick aspects
of biological systems and are an effective summary of prior biological knowledge. Thus,
it is important to make sensible use of these external sources of information.
This thesis details research conducted in an interdisciplinary setting and thus the
Introduction will detail some common aspects that appear across each chapter that
follows. Briefly, the Introduction will detail the flow of genetic information, describe
different types of HTS, as well as detail various forms of external information avail-
able either as databases or raw data sources. Finally we briefly describe the statistical
challenges and novel contributions associated with each chapter of the thesis.
1.1 the flow of genetic information 3
Figure 1.1: Schematic of the Central dogma of molecular biology. An illustration of
the central dogma of molecular biology, a simplified conceptualisation of
the flow of genetic information within the cell. Information stored in DNA
is transcribed into messenger RNA which can then move outside of the nuc-
leus and is translated into a functional protein. Source: Wikipedia Commons.
1.1 the flow of genetic information
It is widely understood that deoxyribonucleic acid (DNA) within the nucleus of the
cell is transcribed into messenger ribonucleic acid (RNA) which in turn translates into
a sequence of amino acids producing proteins outside of the cell (Figure 1.1). DNA is
composed of four nucleotides: A adenine, G guanine, C cytosine or T thymine, which
bind in a double helix structure. RNA is also composed of four nucleotides: A adenine,
G guanine, C cytosine or U uracil, which makes a single strand. Protein is made of
a sequence of amino acids, each produced with its own codon. This simplified frame-
work is termed the central dogma of molecular biology, describing the flow of genetic
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information from the nucleus to the organism. In reality many other mechanisms are
at play, including reverse transcription, non-coding RNA, and epigenetic effects such
as DNA methylation and histone modifications.
Biological changes can occur along any stage of the central dogma, including but not
limited to: changes in the DNA sequence itself, termed mutations; differences in which
strand of DNA transcribes into RNA, termed allele-specific expression; and differences
in the amount of RNA produced between samples, termed differential expression. Data
obtained from HTS can enable statisticians and researchers to analyse these biological
changes.
1.2 high throughput sequencing
High throughput sequencing (HTS) is a technique that identifies the sequence of short
lengths of DNA (Tucker et al., 2009). This technology is not limited to measuring only
DNA, but can be adapted to special circumstances to study specific biological systems.
For instance, RNA can be converted into complementary DNA (cDNA) followed by
HTS to obtain measures of RNA abundance (Figure 1.2). In this thesis we will consider
three main types of sequencing, namely RNA-Sequencing, single cell RNA-Sequencing,
and Whole Exome Sequencing, which differ in subtle but crucial ways. Rather than
traditional low-throughput and expensive Sanger sequencing, HTS has allowed for
faster and increasingly cheaper sequencing of DNA (Schuster, 2007).
While HTS platforms differ in their chemistry and protocols, their processed outputs
are generally similar. The sequencing platforms take a sample of fragmented RNA as
input and then read off between 25 and 400 base pair regions at the ends of these frag-
ments. The output of these sequenced regions, sequences of base pairs, are referred to
as reads. These reads are used to infer the presence and quantity of RNA in the sample.
The development of HTS technologies has made it possible to sequence the entire set of
genes or transcripts, named the transcriptome, at a much higher resolution and cover-
age than was previously available. This, combined with its high level of reproducibility
(Mortazavi et al., 2008) and falling cost, makes HTS technologies the ideal choice for
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Figure 1.2: Flow chart of a high throughput sequencing processing. Once RNA (or
DNA) is isolated, complementary DNA is produced and short sequencing
reads obtained using a high throughput sequencing machine. These short
sequence reads are aligned to the reference genome or transcriptome. This
results in data comprising the sequence read itself, as well as the position
in the genome, and specifically to which gene, the read aligns to. Source:
McQueen et al. (2015) reproduced under creative commons licence.
transcriptome analysis. One of the most prominent sequencing platforms is Illumina,
in which the overwhelming majority of data presented in this thesis comes from.
The output of this technology is a set of short sequence reads. These can be aligned
to a reference genome or transcriptome (Figure 1.2) (Dobin et al., 2013; Liao et al., 2013;
Langmead et al., 2009; Engström et al., 2013), or alternatively used to estimate the tran-
scriptome (Trapnell et al., 2010), with various analyses applied pertaining to the specific
question of interest. One such type of analysis is to identify allelic imbalance or allele
specific gene expression, described further in Chapter 2. Another is to characterise the
abundance of RNA within and between samples including single cells, which we will
elaborate on in Chapters 3 and 4. Another analysis approach is to consider changes
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in the sequence itself to identify somatic mutations in the DNA, described further in
Chapter 4.
RNA-Sequencing (RNA-Seq)
RNA-Seq is a technique used to obtain short sequence reads from messenger RNA
(mRNA) (Wang et al., 2009). Once aligned to the reference genome or transcriptome,
the number of RNA-Seq reads aligning to a particular location or gene can represent
the number of mRNA transcripts present in the sample (Mortazavi et al., 2008). Thus
a typical analysis of data stemming from RNA-Seq data is to identify differential ex-
pression of genes, i.e. which genes tend to have more or less of the mRNA product in
the corresponding sample (Ritchie et al., 2015; Robinson et al., 2010; Love et al., 2014).
Further analysis can be performed, such as identifying which gene sets, pathways or
Gene Ontology (Ashburner et al., 2000) terms are over- or under-expressed between
sample groups (Subramanian et al., 2005; Wu et al., 2010; Wu and Smyth, 2012; Young
et al., 2010a). Multiple RNA-Seq datasets can be integrated using batch effect correc-
tion techniques such as Removing Unwanted Variation from RNA-Seq Data (RUVSeq)
(Risso et al., 2014) and ComBat (Johnson et al., 2007). In addition to this typical analysis
approach, other investigations can be made, including identifying allelic imbalance (de-
scribed further in Chapter 2), and differences in gene expression correlation structure
(see Chapter 4).
Despite the widespread adoption of RNA-Seq in biological studies, challenges re-
main in the analysis of RNA-Seq data. Characteristics of genetic architecture such as
GC content and transcript length contribute to biases in the resulting data from RNA-
Seq and require correction (Zheng et al., 2011) as well as normalisation (Li et al., 2015c),
which in turn affects the assumptions underpinning the statistical analysis of these
data. A host of methods exist for processing and analysis of RNA-Seq data (Conesa
et al., 2016) with specific aims in mind, and ascertainment of the ideal analysis methods
are under development.
While in this thesis we focus mainly on sequencing on messenger RNA molecules,
RNA-Seq encompasses a number of types of RNA, including small RNAs including
microRNAs and silent interfering RNAs (Huang et al., 2010), with varying sequence
1.2 high throughput sequencing 7
designs including cap analysis gene expression (CAGE) (Shiraki et al., 2003) to ob-
tain transcription start sites, as well as exome capture RNA-Seq (Cieslik et al., 2015)
to sequence degraded RNA. Experimental protocols involving RNA-Seq increasingly
include internal controls such as spike-in sequences from other commonly bacterial
organisms like the External RNA Control Consortium (ERCC) (Baker et al., 2005) and
sequin spike-ins (Hardwick et al., 2016) to facilitate standardisation across samples and
aid in normalisation (Burgess, 2016).
Single Cell RNA-Sequencing (scRNA-Seq)
Profiling the entire transcriptome for single cells has in the last decade become an
increasingly feasible and useful tool in biological research (Shalek et al., 2013). The
unprecedented ability to obtain measurements of the entire transcriptome at the res-
olution of a single cell has led to numerous insights into transcriptional heterogeneity
across and within cell types (Buettner et al., 2015; Gao et al., 2016). While many tech-
nical aspects of scRNA-Seq are similar to that of the aforementioned traditional or bulk
RNA-Seq, there exist unique statistical challenges associated with analysis of scRNA-
Seq data (Brennecke et al., 2013; Kim et al., 2015), two main issues being the sparsity of
data as well as apparent bimodal distributions of non-zero expression values for cells.
Despite these challenges, many opportunities exist for obtaining biological insights,
described in more detail in Chapter 3.
Whole Exome Sequencing (WES)
Approximately 2% of the DNA sequence contains protein coding sequences, termed
the exome (Makałowski, 2001; ENCODE Project Consortium, 2004). WES is a technique
that obtains short sequence reads from the part of the DNA that produces mRNA,
which in turn can produce protein sequences. As opposed to Whole Genome Sequen-
cing (WGS), WES is a much cheaper alternative, allowing very high sequence depth,
leading to high statistical power in detection of changes, as well as profiling many
more samples than WGS, enabling large population-based studies (Meienberg et al.,
2016). The trade-off however is the inability to capture genomic changes in regions of
the genome that are not protein coding regions, potentially missing important changes
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in the DNA sequence. WES is of particular use to identify the protein coding DNA
sequence of cancer tumours and in particular the somatic changes occurring between
surrounding normal tissue in the same individual, and has been used extensively by
The Cancer Genome Atlas consortium (cancergenome.nih.gov/) in profiling thousands of
cancer samples. Identification of somatic mutations using WES is described in more
detail in Chapter 4.
1.3 external information
Throughout this thesis we make extensive use of different forms of external informa-
tion. This includes curated databases including networks, as well as other specialised
data sources such as the Cancer Genome Atlas (TCGA) (cancergenome.nih.gov/) and
datasets curated within the Gene Expression Omnibus (GEO) (ncbi.nlm.nih.gov/geo).
These sources of information stemming from outside of the dataset on hand offer a
rich setting for developing statistical and methodological approaches, supplementing
insights from data produced ‘in-house’, as well as leading to biological insights.
1.3.1 Biological networks
Biological networks can aid in understanding the role of genes, placing them in the
context of their environment, function and influence. Biological networks help facil-
itate biological discovery, consolidating prior knowledge about biological systems, or
effectively summarising information from unrelated data sources. Networks can be
curated a priori, and stored in databases, or estimated from other data sources. There
are flavours of biological networks that can be useful in various contexts and it is very
important to understand the network used, and its potential drawbacks and biases.
Figure 1.3 describes the main parts of a biological network, including nodes and direc-
ted or undirected edges. Networks have previously been used in the context of gene
expression (Taylor et al., 2009), identifying ‘party’ and ‘date’ hubs along a PPI network,
determined by the differing levels of correlation coexpression in genes among samples
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Figure 1.3: Description of a network. Networks comprise of nodes or vertices, and
edges. Nodes are connected to other nodes via directed or undirected edges,
imparting some information about the relationship between the nodes they
represent.
between two conditions, such as good and poor prognosis patient groups. As such
a number of disturbed gene expression hubs were identified to be related to breast
cancer. In addition, methods have aimed to build networks in silico based on gene-
gene coexpression (Stuart, 2003; Xia et al., 2006; Fuller et al., 2007; Reverter and Chan,
2008; Huynh-Thu et al., 2010; D’haeseleer et al., 2000), circumventing the use of net-
work information based on prior knowledge. Methods involving network approaches
have uncovered insightful regulatory modules in disease networks (Ideker et al., 2002;
Ma and Wong, 2011; Dittrich et al., 2008) using curated networks and available data
to identify subnetworks worth pursuing for further biological analysis (Barabási et al.,
2011). In summary, network methods have aimed to shed light on interesting regions
of the biological space and have hinted towards meaningful explanations of the phe-
nomena observed.
Protein-protein interaction networks
PPI networks are useful to place genes into the context of their corresponding pro-
cesses. PPIs have been extensively used to aid in biological network analysis, as a
tool to reduce the computational search space for algorithms, or to prioritise relation-
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ships identified a priori. Detailed discussions and comparisons of PPI networks are in
Schramm et al. (2013b) and Barabási et al. (2011). Publicly available PPI databases exist,
with varying degrees of reliability and completeness, such as BioGRID (Breitkreutz
et al., 2007), Human Interactome (Rolland et al., 2014), Human Protein Reference Data-
base (HPRD) (Keshava Prasad et al., 2009), iRefWeb (Turner et al., 2010), MetaCore
(Ekins et al., 2007), and consolidative networks such as HIPPIE (Schaefer et al., 2012). A
key issue with PPIs however is that they offer a static snapshot of a truly dynamic net-
work (Davis et al., 2012), and that information may be lost mapping proteins to genes,
there being a many-to-one mapping of proteins to a single gene, with potential inform-
ation loss when identifying interactions in an experimental setting versus within an
organism. That is, the two proteins may interact when placed together, but would not
come into contact within the cell at all. Despite these potential issues, PPIs offer a huge
amount of a priori biological information that can be utilised in subsequent network
analysis in many biological study and disease contexts (Taylor et al., 2009; Taylor and
Wrana, 2012; Genovesi et al., 2013; Schramm et al., 2013a), and is further utilised in
Chapter 4.
1.3.2 Public data sets
The Cancer Genome Atlas
TCGA (cancergenome.nih.gov/) is a comprehensive and coordinated effort to accelerate
the understanding of the molecular basis of cancer through the application of genome
analysis technologies, including large-scale genome sequencing. TCGA data describes
33 different tumour types based on paired tumour and normal tissue sets collected
from 11,000 patients using seven different data types. The aim is to build up a com-
prehensive ‘atlas’ in order to be able to unpick what drives cancer incidence and pro-
gression to later stages or death. Many studies have made use of TCGA data in order
to develop approaches to lead to biological insights or to supplement their own data
with this large dataset as a means of validation. We make use of data from TCGA in
Chapter 4.
1.4 outline of the thesis 11
Gene Expression Omnibus
Many datasets once published are available online via GEO, and can be used to further
biological knowledge. Caveats include that information such as batch labels may be
unavailable, or that the experiments may not be identical to each other. However, the
benefits of making use of these datasets to drive discovery are great, especially as a
way of performing validation of observations. Datasets curated within GEO are used
extensively in Chapter 3.
Figure 1.4: Chapter summary. Description of following chapters in terms of data ana-
lysed including the research area, organism, sequencing platform, dataset
types and experimental set up.
1.4 outline of the thesis
This thesis proposes several approaches to address various biological questions over a
range of research areas, sequencing platforms, organisms, and experimental designs.
Some of these methods, concepts, analyses, and results have already been published
(or are currently under review) by the author. Figure 1.4 summarises the topics of
analysis over each chapter throughout this thesis.
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The first of these, Chapter 2, proposes a method to characterise imbalance of ex-
pression from differing alleles with application to livestock genomics and includes
work published in Ghazanfar et al. (2017). Chapter 3 outlines a novel methodology for
identifying highly expressed genes and cells for single cell RNA-Sequencing data and
includes work published in Ghazanfar et al. (2016). Finally, Chapter 4 develops novel
frameworks for estimating cancer mutation-expression networks for matched gene ex-
pression and somatic mutation data, as well as relating somatic mutation driver gene
scores to network correlation disturbance between groups of unmatched cancer pa-
tients; and includes work published in Ghazanfar and Yang (2016).
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gene expression allelic imbalance in ovine brown adipose tissue 14
Within any species population, variation in the DNA sequence exists, leading to the
vast array of differences between individual organisms. A key aim of population ge-
netics is to identify the sources of this variation, that is, identifying natural genetic
variants that affect gene expression and thereby functional traits, especially in the con-
text of human disease and agricultural species. Identification of alleles that directly
alter mRNA expression and thereby biological function can be challenging as it is dif-
ficult to isolate the sources of these genetic variation, for instance DNA regulatory
sequences or epigenetic mechanisms (Deng et al., 2014). Identifying instances where
there are differences in the abundance of mRNA originating from each allele, termed
allelic imbalance (AI), provides a unique opportunity to identify genes impacted by
direct cis-acting variants, as opposed to indirect trans-acting effects that impact the
expression of both alleles in this genotype. However, the identification of AI remains a
challenging task technically and statistically. High throughput sequencing obtains se-
quence reads of mRNA and thus enables characterisation of AI, something previously
infeasible on the genome-scale using microarray technology.
This chapter describes a novel analytical pipeline in order to assess AI in RNA-Seq
data. We describe the analysis of data from an experiment with sheep which provides a
further important challenge: working with a partially known genome. This chapter also
assesses some of the biological significance of the discovered genes. A number of tools
aiming to identify AI require parental DNA in order to make inferences (Stevenson
et al., 2013; Bell et al., 2013; Pandey et al., 2013), or are restricted to measuring a set of
technical replicates, as opposed to a cohort of biological samples (Skelly et al., 2011).
This chapter offers a framework for identifying AI in the case where parental DNA is
not available and using a cohort of biological samples, representing a sample from the
population. We address statistical challenges associated with detecting AI including
the reliability of SNP discovery and filtering from RNA-Seq mRNA expression data
and developing a statistical count model that assesses AI in gene expression at the
heterozygous loci. The current study focused on discovery of AI using natural genetic
variants in the form of single nucleotide polymorphisms (SNPs) as allelic reporters
in a population. We identified a ranking of genes with evidence of AI, using RNA-
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Seq data derived from brown perirenal adipose tissue taken from a cohort of late
gestation fetal lambs and demonstrated strong enrichment of these genes in biological
processes collectively related to lipid metabolism and mitochondrial function. These
functions suggest that specific genetic variations in the population are preferentially
influencing energy homeostasis, cell-cell contacts in tissue and protein synthesis. All
of these functions, particularly in adipose tissue and skeletal muscle, may be affected
by strong genetic selection as they influence primary production traits in sheep.
2.1 motivation
2.1.1 Biological context
A major aim of population genetics is the identification of genetic variants and their
biological effects. Genetic variants are important for understanding fundamental bio-
logical issues such as gene function. In agriculture, genetic variants are important for
predicting and improving production traits. For a specific DNA variation that impacts
function in a population of diploid animals there are three possible genotypes, the ho-
mozygote wild type, the homozygote variant, and the heterozygote consisting of one
copy of the wild type and variant alleles. In medicine, genetic variants underlie many
aspects of human health and hence are of particular interest. Identification of these
genetic variants may hasten the discovery of novel solutions to human diseases and
enable selective breeding of agricultural species with the most desirable production
traits.
Genetic variation can directly impact the amino acid sequence of the protein encoded
by a gene, and thereby affect the function of the protein, or it can modify the level of
expression of a gene (Chamberlain et al., 2015). In the former case the variant is present
within the transcribed region of a protein-coding gene. In the latter case the variant
can lie within the coding region of a gene and affect the expression of that gene or the
variant can lie outside the gene - e.g. in gene promoters or distant regulatory elements
such as enhancers (Maurano et al., 2012). This is termed as a ‘cis’ effect, as the genetic
variant lies close to or within the affected gene as opposed to a ‘trans’ effect stemming
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from some indirect genetic influences. AI of gene expression refers to the situation
where the two parental alleles do not exhibit equivalence of expression and this can be
caused by a number of mechanisms such as differential epigenetic modification.
Within the last decade there has been an increased focus on determining AI using
data derived from high throughput sequencing (HTS) technologies such as RNA-Seq
(Mortazavi et al., 2008). The development of these technologies has enabled measure-
ment of expression of genes and transcripts in a high-throughput manner. Transcripts
correspond to the gene fragment that does not include introns, with the entire set of
transcripts referred to as the transcriptome. Similar to its predecessor, gene expression
microarray technologies, RNA-Seq can capture the level of expression of each gene
within a tissue but typically with greater sensitivity and specificity (Mortazavi et al.,
2008). RNA-Seq additionally allows discovery of novel transcripts and splicing vari-
ants of genes (Costa et al., 2013). Data generated from RNA-Seq counts the number of
reads mapped to each gene or transcript and, in some analyses, this count is normal-
ised to the size of the transcript. Typically, this information is then used to characterize
differential gene expression between two or more groups of samples.
As RNA-Seq is based on sequence read technology, it also samples genetic variations
in the transcribed mRNA sequences (Quinn et al., 2013). SNPs can be used as conveni-
ent markers to enable measurement of the expression of each allele within mRNA
samples from a genetically diverse population. At heterozygous loci, AI is sometimes
present, where significantly differing levels of transcript from each allele are observed
caused by cis-acting genetic variation. Importantly, trans-acting effects of genetic vari-
ation impact the expression of both alleles equally and thus imbalanced expression
at a heterozygous locus is a definitive signature of a cis-acting genetic variant or ge-
nomic imprinting occurring through parental allele specific epigenetic modifications
(Ferguson-Smith, 2011; Nikaido et al., 2003; Luedi et al., 2007; Hutter et al., 2010). The
genetic variants driving AI associated with specific genes are likely to remain hidden,
but as they act via cis mediated effects, they must be in the vicinity of the gene.
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2.1.2 Technical and statistical challenges
A first technical challenge for this study is the organism involved. In most previous
research on AI, studies were carried out either in humans or other model organisms
where well-curated reference genomes and transcriptomes are readily available. The
dataset used is from a study involving sheep, which is associated with a high qual-
ity ‘draft’ ovine genome sequence and draft gene annotation. Thus there is an added
difficulty in the initial analysis stage, read mapping, where collected fragmented RNA
sequences are matched to the reference transcriptome. A read originating from the non-
reference (alternate) allele is less likely to successfully map to the correct genome loca-
tion, due to algorithm parameters allowing a threshold of mismatches to the reference
sequence in the read mapping software. Consequently selecting a set of parameters
in the read-mapping algorithm that tolerates more mismatches is desirable (Stevenson
et al., 2013). While incorrect read mapping may then increase, the outcome is equal
mapping of reads originating from the reference and alternate alleles, leading to a
more accurate characterisation of AI. This issue is present even for very complete and
accurate reference genomes, but even more so in the case of the ovine genome, where
more mismatches can be expected to arise, due to errors in the draft reference genome
assembly.
Following read mapping to the genome, a set of genetic variants needs to be iden-
tified, typically achieved by considering SNPs. One option is to consider a database
of known SNPs such as dbSNP (Sherry et al., 2001). However, novel SNPs cannot be
identified in this manner, which is a greater issue in the case where there is a draft
reference genome and incomplete definition of the SNP variants in this species as op-
posed to other species. Our approach has therefore been to identify SNPs in a de novo
manner from the observed mRNA sequences.
Another important issue is the large dynamic range of gene expression. Contrary to
DNA-Seq where we can expect somewhat consistent coverage of reads there is a huge
variability in the number of reads associated to different SNPs. This presents a technical
difficulty in teasing out biologically relevant signal as opposed to simply identifying
statistical signal due to inflated power of detection. To this end we propose an approach
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to directly subsample reads repeatedly to obtain a more consistent detection power of
AI across SNPs.
Finally, statistical issues associated with multiple comparison correction arise when
one must combine results from SNPs to the level of genes in the presence of correlations
among such SNPs. In addition, the differing numbers of SNPs per gene contribute
to difficulty in effective adjustment for multiple comparisons. Thus, the assumptions
underlying standard multiple testing adjustment or false discovery rate (FDR) is likely
to be less appropriate than typical omics studies. To this end we considered other
statistical techniques for identifying genes with AI, with a focus on determining a
reliable ranking of genes with AI.
2.1.3 Related approaches to AI
Skelly et al. (2011) proposed a Bayesian hierarchical model to identify genes exhibit-
ing AI among technical replicates of yeast strains utilising RNA-Seq data. This was
performed by constructing a hierarchical model for allelic read counts, modelling the
counts as binomially distributed with a parameter corresponding to the probability
of the alternate allele, which is itself modelled using a gene-specific beta distribution.
The algorithm relies on not only the RNA-Seq data but also genomic DNA-Seq data to
be available in order to correctly estimate the parameters in the model, using Markov
Chain Monte Carlo (MCMC) approaches. This approach limits one to consider studies
or experiments utilising only one biological sample, and thus could not be applied to
the case study data in this thesis, even if the associated DNA-Seq data were available.
Another approach defines a test statistic combining both the magnitude of gene ex-
pression and allelic fraction to identify genes with AI and regulatory regions related
to them using human RNA-Seq data (Serre et al., 2008).
The technical and statistical issues associated with identifying and quantifying AI
from RNA-Seq data have previously been highlighted by various authors. Degner
et al. (2009) detail the potential read mapping biases towards the ‘reference’ allele,
and Stevenson et al. (2013) identified strategies to address the potential read mapping
biases, including multiple iterations of mapping the RNA-Seq reads to the genomes
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of each of the individual’s parents. Other software tools such as Allim (Pandey et al.,
2013) and the research of Bell et al. (2013) make use of genomic data from the parents
of the individual to identify AI and genomic imprinting. However these last methods
rely on genomic data from the parents of the individual of interest, which may not be
available.
2.2 methods
The sequence of methods for identifying genes with AI is illustrated in Figure 2.1. The
steps are listed below and described in detail in Sections 2.2.1 and 2.2.2.
1. Data preprocessing:
a) Reads are mapped to the reference genome;
b) A set of de novo SNPs are identified from the data;
c) For each SNP and sample, a genotype is determined, and homozygous SNPs
are removed;
d) Read counts are obtained for each SNP, sample and allele, and randomly
downsampled a number of times;
2. Modelling
a) Read counts for these samples are used in a Poisson model to test for AI;
and
b) Putative AI genes are identified by combining SNP results to the gene level.
2.2.1 Data preprocessing
The starting point for data analysis is a collection of sequence read files produced by
HTS. The first step is to align reads to a reference genome. This should be performed
using a set of parameters that do not harshly penalise mismatching nucleotides, in
line with suggested guidelines (Stevenson et al., 2013). In the present study, we used a
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Figure 2.1: Workflow of Data Analysis. Once RNA is extracted and sequenced, se-
quence reads are mapped to the reference genome; a set of de novo SNPs
are identified from the data for each SNP and sample; a genotype is de-
termined, heterozygous samples are selected; downsampled read counts
for these samples are used in a Poisson model to test for AI; putative AI
genes are identified by combining SNP results to the gene level.
maximum mismatch threshold of ten nucleotides for this step. The data used in this
chapter originated from a study of perirenal adipose tissue (PRAT) taken from sheep
fetuses in late gestation. RNA-Seq data in the form of 100 bp paired end reads were
generated for 18 samples. RNA-Seq reads were mapped to the ovine reference genome,
Oar v3.1 (Jiang et al., 2014) using the STAR RNA-Seq aligner (Dobin et al., 2013). More
details are given in Appendix A. A total of 7,631,907 SNPs were identified de novo in
the mapped sequence data using the Genome Analysis ToolKit (GATK) (DePristo et al.,
2011). This number is consistent with similar discovery rates in other sheep studies
(Kijas et al., 2009). SNPs with low read counts (at least 10 reads for both alleles for at
least five of the 18 samples) were removed, as were SNPs in known repeat regions,
or outside of annotated genes. The details of this process are provided in Appendix
A. A SNP was determined as homozygous or heterozygous using the output from the
GATK’s UnifiedGenotyper tool. This rigorous progressive filtering process reduced
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Figure 2.2: Scatterplot of allele-specific expression. Scatterplot of read depth per SNP
per sample. X-axis corresponds to reads (log scale) for the reference allele,
and y-axis corresponds to reads (log scale) for the alternate allele. Blue
points correspond to SNPs that pass the read-depth based filtering, and red
points correspond to those that, in addition to the previous filter, pass the
annotation-based filtering step.
the number of SNPs for further analysis to 24,355, a reduction factor of over 300. The
read depths associated with these SNPs are summarised in Figure A.1 by samples and
Figure 2.2 by both samples and SNPs, highlighting those SNPs retained after filtering.
2.2.2 A Poisson count model for allelic imbalance
After SNP identification and filtering, we obtain two read counts for each heterozyg-
ous locus per sample. All reads covering the SNP are considered, and the number of
reads NA and Na matching the reference (A) and alternate (a) alleles respectively are
computed. Any reads with another nucleotide at the SNP location (from either read
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sequencing or mapping errors or due to an additional allele within the population at
the same position) are ignored. The genotype call, AA, aa or Aa is also available from
the SNP output in GATK.
Using the gene expression data associated with the heterozygous loci, we test for AI
at each SNP. AI cannot be detected in homozygous samples in this experimental setting,
so testing is restricted to samples deemed to be heterozygous at the particular SNP
marker position. Using the read count data for these samples, we derive a likelihood
ratio test (LRT) based on a Poisson model to test for AI. For the given locus we have
read counts Xjk where j = 1, ...,n represents the individual, and k = 0, 1 represents the
reference and alternate allele respectively. Assume Xjk has a Poisson distribution with
mean λjk. We model λjk as

log λj0 = αj + δ
log λj1 = αj − δ
or
log λjk = αj + (−1)kδ
where αj represents overall abundance (gene expression) for individual j, and δ rep-
resents the AI.
Likelihood
The likelihood of an observation Xjk is
l(λjk;Xjk) = e−λjkλ
Xjk
jk /Xjk!
and the negative log likelihood is
L(λjk;Xjk) = λjk −Xjk log λjk + logXjk!.
Ignoring terms that do not depend on λjk, we have
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Ljk = λjk −Xjk log λjk
or in terms of αj and δ
Ljk = L(αj, δ;Xjk) = eαj+(−1)
kδ −Xjk(αj + (−1)
kδ).
Now the log likelihood for the pair of counts (Xj0,Xj1) is
Lj = Lj0 + Lj1
which is equal to
Lj = e
αj(eδ + e−δ) −αj(Xj0 +Xj1) − δ(Xj0 −Xj1).
Restricted likelihood L˜j
We are mainly interested in the imbalance parameter δ, so we initially optimise the
likelihood over the abundance parameters αj to produce the restricted log likelihood
L˜j(δ) = min
αj
Lj(δ,αj).
First we find the maximum likelihood estimate (MLE) for αˆj by taking the partial
derivative of Lj(δ,αj) with respect to αj and equating it to zero. Therefore the restricted
log likelihood is
Lj = e
αˆj(eδ + e−δ) − αˆj(Xj0 +Xj1) − δ(Xj0 −Xj1).
which after substituting the MLE for αˆj
αˆj = log(Xj0 +Xj1) − log(e
δ + e−δ)
simplifies to
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L˜j(δ) = (Xj0 +Xj1) − (Xj0 +Xj1)(log(Xj0 +Xj1) − log(eδ + e−δ)) − δ(Xj0 −Xj1).
Ignoring terms that do not depend on δ gives the simplified expression
L˜j(δ) = (Xj0 +Xj1) log(eδ + e−δ) − δ(Xj0 −Xj1).
We can now sum over all individuals to obtain the overall restricted log likelihood
L˜(δ) = (X0 +X1) log(eδ + e−δ) − δ(X0 −X1)
where

X0 =
∑n
j=1 Xj0
X1 =
∑n
j=1 Xj1
are the sums of read counts over all individuals for each allele.
MLE for δ
We now minimise L˜δ over δ to obtain the MLE. Taking the derivative with respect to δ
and equating to zero gives the MLE of δ
δˆ =
1
2
log
(
X0
X1
)
.
Likelihood ratio test statistic
The LRT for the no-imbalance null hypothesis
H0 : δ = 0
uses the minimised log likelihood
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L1 = L˜(δˆ)
= (X0 +X1) log(eδˆ + e−δˆ) − δˆ(X0 −X1)
which further simplifies to
L1 = (X0 +X1) log(X0 +X1) −X0 logX0 −X1 logX1.
The likelihood ratio statistic is
χ2 = −2(L1 − L0)
where
L0 = L˜(0) = (X0 +X1) log 2.
Thus
χ2 = 2X0 logX0 + 2X1 logX1 − 2(X0 +X1) log((X0 +X1)/2).
Under the null hypothesis, χ2 follows a χ21 distribution, thus allowing direct calculation
of a p-value for each SNP. Also note that χ2 = 0 if X0 = X1, and thus the associated
p-value is 1. We furthermore note that this test is symmetric in terms of choice of
reference and alternate allele, thus we are not forced to specify which is which in our
test.
Sufficient statistics and testing
Identifying sufficient statistics for the test allows for efficient storage and use of ob-
served data. The sufficient statistics for the above test are the sums of read counts for
each allele, taken over all individuals with a heterozygous genotype at the given locus.
Once a set of p-values per SNP is calculated using the χ21 distribution, there is a need
to combine p-values to make gene-level inferences. All SNPs in RNA-Seq data are asso-
ciated with a gene, as RNA-Seq captures transcript sequences from genes, and we also
need to be able to make inferences at the gene level. The immediate issue is that the p-
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values for SNP within a gene are not independent, and therefore traditional methods of
correcting for multiple comparisons such as Benjamini-Hochberg false discovery rate
(FDR) correction (Benjamini and Hochberg, 1995), while potentially useful, must be
interpreted with care. For example, the actual false discovery rate of an ‘FDR’ method
may be much lower than the nominal or target rate due to the lack of independence
of many SNPs. The problem is complicated somewhat by the fact that some genes con-
tain more SNPs than others - generally, longer genes contain more SNPs than shorter
genes. Our approach has been to consider the most significant SNP as representative
of the gene. The complex structure of the data and the processing mechanisms makes
it challenging to build the null distribution for the data to be analysed at the end of
the processing steps, for example it is conceivable for there to be some SNPs within a
gene that are AI while there are others that are not. Thus, care must be taken when
employing multiple-testing correction procedures, to the end of interpreting evidence
for AI. The ranking of genes in terms of evidence for AI is perhaps more informative
than a list of significant genes.
2.3 application to ovine fetal adipose data
We applied this approach to the 18 ovine fetal adipose samples (more details on
samples provided in Appendix A and RNA-Seq data in Table A.1) and performed
the test for AI. We describe some results and investigation of these below.
2.3.1 SNP filtering
We considered how the number of SNPs obtained changed with varying minimum
coverage thresholds, in terms of the number of SNPs and genes identified, and the
proportion of previously identified SNPs via dbSNP (version 143). We found marked
differences across all minimum thresholds tested, namely at least 5, 10, 20, 30, 50 or 100
reads for at least 5 of the 18 individuals in the cohort, with numbers of SNPs ranging
from 2719 to 33747, numbers of genes ranging from 931 to 7033 and proportion of SNPs
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Figure 2.3: Coverage threshold effects on SNPs. Graphs of number of SNPs identified,
number of genes associated with the aforementioned SNPs, and proportion
of SNPs previously identified in dbSNP for varying values of minimum cov-
erage thresholds. A minimum coverage threshold of 10 reads was selected
(larger blue circle).
identified in dbSNP ranging from 85.4% to 92.4% (Figure 2.3). Using this information
we selected a minimum coverage threshold of 10 reads, as it mitigates between too
many SNPs, thereby introducing many spurious hits and false positives, and too few
SNPs, thereby reducing our ability to discover novel SNPs and genes with AI. This
selection was less stringent than the 30 RNA-Seq reads threshold used by Ardlie et al.
(2015).
We identified a total of 7,631,907 SNPs and filtered these to a total of 24,355 SNPs
based on read-depth, and gene annotation. Among these 24,355 SNPs identified, 13,881
were found to be synonymous variants, that is they did not lead to any change in the
associated amino acid. Of the 10,474 nonsynonymous variants, 4,831 and 3,470 were
missense variants (premature stop codon) and 3’ UTR variants, respectively, among
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other categories detailed in Table A.2. Notably, there were 18 stop codon gains and 6
stop codon losses as well as 8 variants that affected splice sites, which collectively have
potential for substantial functional impacts.
2.3.2 Identification of AI Genes and Gene Rankings
Using the set of filtered SNPs, the Poisson count model LRT was applied. We combined
SNPs to the gene level by taking the minimum of the unadjusted p-values over all
SNPs within a gene. However, the minimum p-value over SNPs within a gene does
not theoretically lead to a uniformly distributed p-value. Typically in such a situation
Fisher’s method of combining p-values would be used, but this assumes the individual
SNP p-values are independent, which is not true in our case. As such, we ordered genes
according to their minimum p-value, and reported these rankings, the top 30 ranked
genes are listed in Table A.3.
2.3.3 Downsampling to reduce bias
Following the identification of AI genes and gene rankings in the previous section,
we observed that the majority of highly ranked genes also exhibited high levels of
gene expression, and thus we observed a high association or confounding between the
overall expression of the genes and the ranking of AI for these genes (Figure 2.4A).
This can be attributed to the increase in statistical power for detecting AI in genes
with higher expression due to higher read counts. As a motivating example, Table 2.1
describes the p-value associated with testing for AI at different total read depths and
imbalance levels. The statistical power to detect a ratio other than 50:50 increases with
the total number of counts, but may not necessarily correspond to biologically relevant
results, and can impinge on identifying true imbalance in cases of low expression.
As a strategy of addressing this issue, we investigated using a downsampling ap-
proach to induce roughly equal statistical power for detecting AI across SNPs, by tak-
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Figure 2.4: (A) Highly expressed SNPs are ranked highly for significant AI when
not downsampling. Curves show the proportion of highly expressed SNPs
(top 5 %) within the top-ranked SNPs using the original method (blue)
and using downsampling (red). (B) Choosing appropriate read depth for
downsampling. Bias as estimated by the absolute Spearman rank correl-
ation between p-value (negative log-transformed) and overall expression
over samples, against variance measured as the median over SNPs of the
variance over 10 repetitions of downsampling at the varying read depths.
(C) Stability of downsampling compared to random selection. For each
number of top ranked SNPs, the number of common SNPs among k = 20
random samples are graphed. The inset graph shows an enlargement of the
original plot between the values of 0 and 24,355, showing that eventually
all SNPs will be included in the list.
ing random subsamples of the data to a similar coverage level. Implementing this
method requires specifying two parameters:
• the downsampling level - how many reads to sample at each SNP, and
• the replication level - how many times to repeat random subsampling.
Figure 2.4 describes some comparisons made between the original approach and
the downsampling approach. We considered SNPs to be highly expressed if they were
above the 95% quantile of the overall gene expression for SNPs, thus we would ex-
pect that overall approximately 5% of top ranking SNPs should be associated with
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Table 2.1: Example explaining rationale of downsampling approach. This table de-
scribes the results in four cases, if there is no AI or if there is AI, and if
the gene expression level, i.e. total read counts, is low or high. When gene
expression level is high, there is more statistical power to detect an unequal
ratio, thus instances of AI for lowly expressed genes can be inadvertently
ignored.
No Imbalance Imbalance
Expression Level Low High Low High
Total reads 100 10,000 100 10,000
Reference reads 51 5,100 60 6,000
Alternate reads 49 4,900 40 4,000
Ratio 51:49 51:49 60:40 60:40
p-value 0.8 0.04* 0.04* 1× 10−89***
highly expressed transcripts. Downsampling was employed by repeatedly sampling
without replacement to 50 reads twenty times, testing for AI, and combining the ranks
of the SNPs over the repeated downsized samples by taking the geometric mean of the
ranks. Figure 2.4A shows that the top ranked SNPs are roughly representative of the
highly expressed genes from which they arise, as we would expect. The coverage level
of 50 reads was chosen by comparing the tradeoff between estimated bias and estim-
ated variance for differing read depths. Bias was estimated as the median correlation
between the overall expression of SNPs and the p-values over multiple iterations. Vari-
ance was estimated as the median variance of p-values over multiple iterations. The
read depths to choose from corresponded to the 5%, 10%, 15%, ..., 100% quantiles of
the overall expression. Using this approach, we observed that the most suitable down-
sampling read depth is approximately 50 reads, shown in Figure 2.4B, as it mitigates
between the overall bias and overall variance. We also considered the stability of the
results of the downsampling method, as it is a non-deterministic method relying on
random selection. We found that there were 154 SNPs that were in the top 200 ranked
SNPs for every downsampling iteration out of k = 20 times (Figure 2.4C), indicating a
highly stable method compared to random selection of SNPs. Importantly, following
the implementation of the downsampling procedure on the case study data, no appar-
ent bias was observed between highly expressed genes and AI ranking (Figure A.2).
This approach was implemented and the 20 top-ranked genes are listed in Table 2.2
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and graphed in Figure 2.5. The results from the original procedure (no downsampling)
are in Table A.3.
We found upon comparison of the ranking of SNPs using the downsampling ap-
proach that certain classes of variants tended to be more highly ranked than expected
by chance, namely missense variants, splice acceptor variants, splice donor variants,
and stop gained variants (Figure A.3), using a one-sided Wilcoxon Rank Sum test
with a significance threshold of 0.01. These variants have the potential of affecting the
mRNA sequence and consequently the amino acid sequence, which can be associated
with variation in the transcripts.
We looked at the concordance of SNP results across genes and found that they were
very highly concordant within genes. We did this by calculating the average of stand-
ard deviations of the rank product for the SNPs and genes, and compared this to
randomly changing the mapping between SNP and genes. After 1000 random shuffles
of the SNP-gene labels, the average standard deviations of rank products had a mean
of 5877.1 and standard deviation 33.9 over the 1000 shuffles, whereas the observed
average standard deviation was 4778.0, indicating a significant level of concordance of
SNPs within genes.
2.3.4 Characterising identified AI genes
Next we aimed to elucidate whether the genes showing AI were preferentially enriched
for functional attributes. We did so by carrying out a functional enrichment analysis
using Gene Ontology (GO) terms. More detail is provided in Appendix A. Importantly,
the background gene list was the set of 5,810 genes corresponding to the filtered SNPs
tested for AI. We identified strong enrichments for multiple terms relating to mito-
chondrial function and lipid metabolism (Table 2.3 for downsampled and Table A.4
for original analysis) and significant enriched terms relating to the extracellular matrix
and endoplasmic reticulum. The strongly enriched mitochondrial and lipid catabolism
functions associated with genes showing AI suggest that genetic variants impacting
energy use are impacting perirenal adipose tissue (PRAT) function and possibly more
broadly other tissues with strong energy demands e.g. skeletal muscle, white adipose
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Figure 2.5: AI scatterplots. For the 20 top ranked genes for AI, scatterplots of read
depths for the reference (y-axis) and alternate (x-axis) alleles, for the highest
ranking SNP for that gene. Read depths are transformed into log2(1 + read
counts). Titles include the genome coordinate and the reference and altern-
ative alleles. Data for all animals are shown, including some that are ho-
mozygous at the locus. Blue points denote individuals with heterozygous
marker genotypes. Red points represent those individuals classified as ho-
mozygous and thus were not included in the AI testing. Dashed lines rep-
resent minimum expression thresholds.
tissue, liver and brain. PRAT is particularly energy intensive in the neonatal lamb as
it protects lambs from hypothermia by inducing nonshivering thermogenesis (Schulz
and Tseng, 2013; Symonds et al., 2012; Yao et al., 2011). Although only representing a
minor percentage of total body weight, activated brown adipose tissue has the capacity
to produce 300 fold more heat/weight of tissue than other tissue (Symonds, 2013). Ac-
centuating the risk of hypothermia in neonatal lambs is their limited energy reserves
and high surface area to volume ratio. Moreover, the rapid growth rate of lambs is also
subject to large energy demands. Production traits such as lamb survival, growth rate,
adiposity and skeletal muscle deposition are likely to be subject to artificial selection
in domestic livestock populations due to their commercial relevance and hence genetic
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Table 2.2: Top ranked 20 gene list for AI analysis incorporating the downsampling
approach. Columns correspond to ranking, gene name, genome coordinates
for the most significant SNP for that gene, and the reference and alternate
alleles for that most significant SNP.
Ranking Gene SNP Ref Alt
1 HSPG2 chr2:243838658 G A
2 AHNAK chr21:40277642 T C
3 PLIN4 chr5:17196981 G C
4 ZNF414 chr5:14800007 G A
5 THUMPD3 chr19:17140258 C T
6 OAS2 chr17:61041703 G A
7 GSTP1 chr21:44692878 C T
8 TALDO1 chr21:49363664 T G
9 ELN chr24:33210385 G C
10 OTUD5 chrX:52870722 C G
11 CLEC3B chr19:54064225 C T
12 KLHL24 chr1:201672375 C T
13 TUBB2A chr20:49441713 A G
14 CBY1 chr3:214283417 A T
15 JMJD8 chr24:521806 G T
16 SRRM2 chr24:2267068 T G
17 AKT2 chr14:48772353 C T
18 RTN3 chr21:41355521 C G
19 AADAT chr2:109981601 A G
20 CCBL1 chr3:7504789 C G
variants that impact on these traits may be expected. The enriched extracellular matrix
terms suggest that genetic variants are present in the population that alter cell-cell and
cell-matrix interactions, which may reflect the capacity for greater cellular hypertrophy
and rates of tissue remodelling during development. This capacity is particularly relev-
ant for adipose tissue and skeletal muscle maturation during postnatal lamb growth.
2.4 discussion
In this chapter we presented an approach for identification of allelic imbalance (AI)
genes, from preprocessing of RNA-Seq data all the way through to functional annota-
tion. In addition, we discussed and addressed the technical and statistical issues as-
sociated with identifying genes with AI in expression. In particular, we addressed
issues associated with read mapping and SNP detection. We also controlled for the
2.4 discussion 34
Table 2.3: Top 10 ranked Gene Ontology Analysis terms for AI analysis, using down-
sampled data. Columns correspond to ranking, GO symbol, name of the
term, the particular ontology (biological process (BP), molecular function
(MF), or cellular component (CC)), FDR-adjusted p-value, number of genes
within the ontology term and number of genes outside of the term. Gene
ontology analysis is described in Appendix A.
Ranking GO term Name Ontology
FDR-
adjusted
p-value
Genes
in
GO
term
Genes
not in
GO
term
1 GO:0019752
carboxylic acid
metabolic process BP
1.90× 10−5 390 5420
2 GO:0006082
organic acid meta-
bolic process BP
2.40× 10−5 430 5380
3 GO:0043436
oxoacid metabolic
process BP
2.40× 10−5 430 5380
4 GO:0005615 extracellular space CC 0.002 297 5513
5 GO:0006520
cellular amino
acid metabolic
process
BP 0.0032 173 5637
6 GO:0006629
lipid metabolic
process BP
0.0032 488 5322
7 GO:0016054
organic acid cata-
bolic process BP
0.0032 103 5707
8 GO:0046395
carboxylic acid
catabolic process BP
0.0032 103 5707
9 GO:0044255
cellular lipid meta-
bolic process BP
0.0038 398 5412
10 GO:0048037 cofactor binding MF 0.0038 133 5677
differences in statistical power due to the dynamic range of expression by employing
a downsampling approach.
Correlations between SNPs within a gene and more widely along the genome hinders
the confident use of multiple hypothesis testing adjustment techniques, such as FDR.
We addressed this issue by selecting the most significant SNP to represent the gene.
The identification of genes that are allelically imbalanced can be hindered by the popu-
lation structure and genetic diversity. Observation of sufficient heterozygous individu-
als is required to obtain a statistically significant result, and due to this issue some
information may be lost. This issue can be overcome by use of larger populations.
We have discussed issues associated with detecting AI from RNA-Seq data derived
from a study on sheep. Given suitable read counts, we developed a Poisson statistical
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Figure 2.6: Plot of SNPs associated with ACSF2 and GOT2. The x-axis is the read
counts for the reference allele and the y-axis is for the alternate allele. Read
depths are transformed into log2(1 + read counts). Red points are those
determined to be homozygous.
model that leads straightforwardly to an elegant likelihood ratio test. The complexity
in such model development is better understood compared to processing issues imme-
diately preceding this step. As with so many cases of developing statistical approaches
in science and other fields, the high-level statistical complexity is dwarfed by a large
number of challenges and difficulties surrounding low-level analysis and highly con-
text specific technical issues.
As discussed in Section 2.1.2, incorrect and/or ambiguous mapping of read frag-
ments to the reference genome is an initial difficulty, and this problem is more sig-
nificant when, as in our case, a less highly-curated organism is the subject of the
experiment. This is still the usual case in agricultural research, as opposed to med-
ical research where the organism of interest is usually very well-studied – often either
humans or a standard model organism such as mouse.
Next we encounter the issue of the large number of potential SNP variants to be
investigated. This presents practical difficulties in terms of computer memory and
computing time, as well as statistical issues relating to multiple testing. This issue
is at one level mitigated, but at another level complicated by the fact that the vast
majority of these SNP variants are not useful for one of several possible reasons: very
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low expression abundance in the samples, very low heterozygosity, low representation
of SNPs in the population, mapping to repeat regions in the genome, or not mapping
to an annotated gene. While the data are more manageable after this severe filtering
in terms of its size, we need to acknowledge that some important ascertainment bias
is present in this selection of SNPs. However, the independent confirmation of many
of these SNPs in other independent sheep populations indicates that the actual SNP
selection process was highly robust.
The final major issue is the issue of expression level and power, the statistical power
for detecting AI is higher when overall gene expression is higher, and there is a huge
range in overall gene expression in these data, as in all gene expression studies. We
have investigated a downsampling approach for dealing with this problem and found
that after downsampling detection of AI appears equally likely at all SNPs. While this
method is not entirely satisfactory from a statistical perspective, since we discard some
information for some SNPs, the benefit of this approach is more valuable in terms of
biological relevance and impact.
A potential extension to the current work is to identify AI in only a subset of samples.
For instance, SNPs associated with the genes ACSF2 and GOT2 (Figure 2.6) appear to
exhibit AI for only some of the samples in the cohort. We may be able to identify
these subsets of samples, by incorporating a latent labelling to our existing modelling
framework.
Another future improvement to the modelling strategy includes using the informa-
tion of the reads for which specific allele counts were obtained, in order to estimate
and understand the correlation structure among multiple SNPs within a gene. This ex-
tension, while promising to uncover a lot of biological information, would also require
some efficient storage and retrieval of the individual RNA-Seq read information, and
is certainly not a trivial task. Perhaps this improved approach may be feasible in the
context of a few genes of particular interest rather than across the entire transcriptome.
3
I N V E S T I G AT I N G S I N G L E C E L L T R A N S C R I P T O M E D ATA F O R
U N D E R S TA N D I N G N E U R O N S
37
investigating single cell transcriptome data for understanding neurons 38
Until the recent explosion of large scale single cell transcriptome profiling, typical
HTS experiments have obtained a measure of gene expression for an aggregate of
millions of cells, ignoring any heterogeneity that may be present among the cell popu-
lation. RNA-Sequencing of single cells (scRNA-Seq) is revolutionary in that this tech-
nology has enabled profiling of the entire transcriptome for the minuscule amount of
RNA present in a single cell. This new platform has added a previously unseen dimen-
sion to gene expression information and presents statistical challenges significantly
different to traditional bulk RNA-Seq data. scRNA-Seq allows elucidation of transcrip-
tional bursting (Suter et al., 2011) and cell heterogeneity which previously did not exist
on the transcriptome scale.
Technical challenges including multimodality and zero inflation directly violate stat-
istical assumptions made for analysis of bulk RNA-Seq, and thus statistical methods
designed for bulk RNA-Seq are not directly transferable to scRNA-Seq. While data
stemming from scRNA-Seq promises elucidation of cell-specific characterisation of
transcriptional bursting and gene coexpression, this must be performed in a special-
ised context.
In this chapter, we offer novel approaches for addressing two distinct aspects of
analysing data arising from scRNA-Seq experiments. We use a series of public mouse
neuronal datasets to demonstrate the method as well as biological insight that can be
obtained from analysing such data. The first aspect is the use of a versatile gamma-
normal mixture modelling framework to identify transcriptional bursting across cells
and as a means of standardising across multiple datasets. We found that transforming
the data into active and inactive gene states allowed for more direct comparison, lead-
ing to identification of maturity marker genes for olfactory sensory neurons (OSNs).
The second aspect is to characterise cell-specific coactivation networks using the ex-
pression states obtained from the mixture modelling framework, thus making use of
the unique characteristics of single cell transcriptomics data. Using the OSN datasets
reveal structures of coactivation for different neuronal cell types across multiple data-
sets, and we find that cell-specific coactivation networks of mature OSNs tend to have
a higher centralisation topological network measure than immature neurons.
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Figure 3.1: Single cell expression data. A sample from a cell population can contain
millions of cells. Bulk RNA-Seq aggregates this huge mixture of cells and
obtains a single value for the expression level of a particular gene in that
sample. scRNA-Seq obtains expression values for each cell, allowing us to
observe cells with no, low or high expression. High expression can come
about through a transcriptional bursting process, where RNA is generated
in short bursts in the cell.
3.1 background
High throughput transcriptome profiling of single cells has dramatically increased in
recent years in the areas of biomedical and basic science research. Typical high through-
put sequencing experiments have obtained a snapshot of gene expression for an ag-
gregate of tens of thousands to millions of cells, and in effect are unable to unpick the
heterogeneity present in the population of cells of interest (Figure 3.1). While experi-
mental techniques such as fluorescence in situ hybridisation have been in existence for
decades, assaying gene expression in single cells has been possible for only a single
gene or very few genes at a time. Similarly quantitative polymerase chain reaction
(qPCR) screens can only be performed on single cells for a small number of genes, in
the order of hundreds of genes.
RNA-Sequencing of single cells (scRNA-Seq) is revolutionary in that this technology
has enabled (1) profiling of the entire transcriptome for small amounts of RNA, on par
with the small amount of RNA present in a single cell, and (2) increasing automation
3.1 background 40
of obtaining these cells, using processes such as microfluidics combined with robotics
(Macosko et al., 2015). scRNA-Seq has been employed to study many types of cells in
a number of organisms, including stem cells, cancer cells and neurons in mouse and
human (Saliba et al., 2014), and has enabled both small-scale interrogations (16 cells
(Scholz et al., 2016)) to very large scale profiling studies (44,808 cells (Macosko et al.,
2015)), showing no signs of slowing down in terms of throughput of cells. Analyses
have aimed to characterise cell heterogeneity (Gu et al., 2015; Diaz et al., 2016), and
to identify cell subtypes using techniques such as dimension reduction and clustering
(Zurauskiene and Yau, 2016; Xu and Su, 2015; Ntranos et al., 2016). Other possible
analyses include differential expression (Kharchenko et al., 2014), and more specific
questions driven by biological models. For instance, a longstanding hypothesis has
been that OSNs in mice express only one odorant receptor gene, termed the ‘one-
neuron-one-receptor’ rule. This was recently tested in single mature and immature
OSNs using scRNA-Seq (Tan et al., 2015), and it was found that immature neurons can
transiently express multiple odorant receptor genes while mature neurons primarily
express a single odorant receptor gene.
Some statistical challenges associated with scRNA-Seq are unique compared to typ-
ical RNA-Seq of bulk cell populations. While shared challenges such as normalisa-
tion, accurate modelling of counts and cross platform comparisons exist, these may
be exacerbated or manifest differently in the presence of characteristics unique to
scRNA-Seq data. The most immediate characteristic of single cell gene expression
count matrices are that there is an abundance of zeroes, i.e. genes with no read counts
(Kharchenko et al., 2014), that persist even after typical standardisation transformations
such as counts per million (CPM) or reads per kilobase per million reads (RPKM). Fur-
thermore, the proportion of zeroes across genes appears to be related to the depth
of sequencing performed, contributing to the challenge of appropriately comparing
between multiple datasets with different levels of read depths achieved.
Another key aspect of scRNA-Seq data is the apparent bimodality of non-zero ex-
pression values (Shalek et al., 2013; McDavid et al., 2014; Kim and Marioni, 2013).
As this phenomenon is also observed in other single-cell gene expression measure-
ment methods such as fluorescence in situ hybridisation (Shalek et al., 2013), it can be
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concluded that this phenomenon is not simply technical artefacts stemming from the
scRNA-Seq experiments. Rather, examining the distribution of gene expression meas-
urements of a given gene over many cells can uncover three distinct transcriptional
states: no expression, characterised by no observed read counts; low expression, where
RNA is present at a low level and possibly undergoing degradation; and high expres-
sion, where RNA may have been produced through a ‘bursting’ process (Suter et al.,
2011) (Figure 3.1). Existing approaches for classifying cells into a low or high expres-
sion state are few, including imposing a strict threshold value, and fitting Gaussian
mixture models (Saraiva et al., 2015).
To this end, in this chapter we offer a versatile modelling framework to identify
transcriptional states as well as structures of coactivation for different neuronal cell
types across multiple datasets. This framework includes
1. a gamma-normal mixture modelling approach to classify each gene into no, low
or high expression within each cell;
2. identification of cell type specific genes across multiple scRNA-Seq datasets; and
3. creation of a uniqueness metric to identify coactivation networks within each cell.
Furthermore, we focused on three specific datasets that studied OSNs, and discovered
that the topology of coactivation networks of each cell changes as the OSN cells mature.
We also demonstrated that this framework facilitates combined analysis of multiple
datasets by recovering known OSN maturity marker genes.
3.2 data collection and preprocessing
A set of nine scRNA-Seq datasets were curated (Table 3.1), all measuring transcrip-
tomes of various neuronal cell populations in mice, with varying numbers of cells, se-
quencing strategies, and overall read depths. Raw sequencing reads were downloaded
from the Gene Expression Omnibus (GEO), the Sequence Read Archive (SRA) or the
European Nucleotide Archive (ENA). Fastq files were each mapped to the mm10 refer-
ence genome using STAR RNA-Seq aligner (Dobin et al., 2013) with default parameters.
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Table 3.1: Description of nine murine neuronal single-cell RNA-Seq datasets. DRG -
dorsal root ganglion.
Author
GEO/SRA
Accession Cells
Cell Type(s)
Read
Length
Median
Read
Depth
Fuzik et al. (2015) GSE70844 83
Excitatory pyramidal
and inhibitory neurons
51 391,449
Hanchate et al. (2015) GSE75413 93
Olfactory sensory neur-
ons
98 3,352,691
Li et al. (2015a) GSE63576 209
Somatosensory DRG
neurons
200 18,300,045
Lovatt et al. (2014) GSE52525 28
Mixed cultures of
dispersed brain cells,
hippocampal pyram-
idal neurons
202 17,727,180
Saraiva et al. (2015)
PRJEB4014,
PRJEB8101,
PRJEB4461
264
Olfactory sensory neur-
ons
200 1,570,234
Tan et al. (2015) SRP065920 143
Olfactory sensory neur-
ons
100 936,016
Tasic et al. (2016) GSE71585 1,809 Cortical cells 89 2,350,114
Usoskin et al. (2014) GSE59739 864 Lumbar DRG neurons 40 86,588
Zeisel et al. (2015) GSE60361 3,005
Somatosensory and
hippocampal C1 neur-
ons
52 496,431
Total 6498
The resulting mapped read files were then converted to bam, sorted and indexed us-
ing Samtools (Li et al., 2009), and read counts for a total of 38806 genes were obtained
using HTSeq-count (Anders et al., 2015) under the mode ‘union’ with other default
parameters. Read counts for multiple runs belonging to the same cell were added to-
gether, resulting in a raw count matrix for 38806 genes and 6377 cells. The data matrix
was further transformed by calculating counts per million mapped reads (CPM) and
taking the shifted log (log2CPM), i.e.
yij = log2
(
1+ 106
rij∑
k rkj
)
,
where rij are the raw read counts and yij the transformed counts for gene i and cell j.
Following this, we fitted gamma-normal mixture models per gene per dataset, initially
removing cells with zero log2CPM values, as described in the next section. Histograms
of the log2CPM values for each gene and cell per dataset are presented in Figure 3.2.
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Figure 3.2: Histograms of log2CPM values of for all genes and cells within each data-
set. Zero values are removed from the histograms, and the percentage of
zero-values given for each dataset. Black lines represent the mixture model
and the other two blue and red coloured lines represent the gamma and
normal mixture components respectively.
3.3 methods
3.3.1 Gamma-normal mixture modelling
To model the distribution of gene expression values, we considered a gamma-normal
mixture model. The gamma distribution is fairly flexible with two parameters, and
takes non-negative values. Similar mixture models have been used in transcriptom-
ics research, for example, Baek et al. (2007) utilised gamma-t mixture models for the
purpose of segmentation and intensity estimation for data stemming from two-colour
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cDNA microarray experiments. We observe that scRNA-Seq gene expression values
on log2CPM scale also take non-negative values and thus this distribution may be
suitable. We may be able to use a simpler distribution with similar properties, such
as the exponential distribution, however this distribution does not effectively describe
the observed data for all datasets (e.g. Figure 3.2 top-left). As well as this, the normal
distribution is a suitable candidate for the second component of the mixture model as
it is fairly well characterised and interpretable. One potential setback of using the nor-
mal distribution is that it is defined over the entire real line, including negative values.
However, in practice, this does not pose a problem as the nonzero probability density
on (−∞, 0) is negligibly small.
Before continuing with fitting the gamma-normal mixture model, we remove the
zeroes from the data, as data arising from scRNA-Seq exhibits an extremely high pro-
portion of genes and cells with zero counts, resulting in ill-fitting model parameters.
The remainder of this section derives the expectation maximisation (EM) algorithm
for fitting the gamma-normal mixture model. We assume that for a given gene, the
non-zero expression values can be described by a mixture of gamma and normal dis-
tributions, where the gamma component corresponds to lowly expressed cells and the
normal components corresponds to the highly expressed cells. Let x = (x1, x2, ..., xn)T
be a vector of non-zero log2CPM expression values for a given gene. The density func-
tions for the gamma and normal component are
f(w,α,β) =
βα
Γ(α)
wα−1e−βw,
and
f(w,µ,σ2) =
1
σ
√
2pi
e
−
(w−µ)2
2σ2
respectively. Let y = (y1,y2, ...,yn)T be a binary vector indicating membership of each
cell in the normal component of the mixture. We assume that yi is generated from an
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independent Bernoulli distribution with probability of success ρ, yi ∼ B(1, ρ) for i =
1, 2, ...,n. Thus, the density function for xi is
f(xi,α,β,µ,σ2, ρ) = (1− ρ)
βα
Γ(α)
xα−1i e
−βxi + ρ
1
σ
√
2pi
e
−
(xi−µ)
2
2σ2 .
The corresponding complete log-likelihood is
`(x, y,α,β,µ,σ2, ρ)
=
n∑
i=1
[
(1− yi) (α log(β) − log Γ(α) + (α− 1) log(xi) −βxi)
+yi
(
−
1
2
log(2piσ2) −
(xi − µ)
2
2σ2
)
+ yi log ρ+ (1− yi) log(1− ρ)
]
.
Let zi = E(yi|rest), i = 1, 2, ...,n be the expectation of yi given the other parameters
and data. We also let Q(α,β,µ,σ2, ρ) ≡ E(`(x,α,β,µ,σ2, ρ)|rest) be the expectation of
the log-likelihood given the observed data, using the current values of the parameters.
In particular
Q(α,β,µ,σ2, ρ)
=
n∑
i=1
[
(1− zi) (α log(β) − log Γ(α) + (α− 1) log(xi) −βxi)
+zi
(
−
1
2
log(2piσ2) −
(xi − µ)
2
2σ2
)
+ zi log ρ+ (1− zi) log(1− ρ)
]
,
and zi = 1/(1+ e−ηi), for i = 1, 2, . . . ,n, where ηi is given by
ηi = α̂ log(β̂) − log Γ(α̂) + (α̂− 1) log(xi) − β̂xi
+12 log(2piσ̂
2) +
(xi−µ̂)
2
2σ̂2
+ log
(
ρ̂
1−ρ̂
)
.
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The above describes the expectation step, while the following parameter updates are
performed simultaneously, forming the M-step,
µ̂ =
∑
zixi∑
zi
,
σ̂2 =
∑
zi(xi−µ̂)
2∑
zi
,
α̂ = Γ−1
(∑
(log β̂+ log xi)(1− zi)∑
(1− zi)
)
,
β̂ =
α̂
∑
(1−zi)∑
xi(1−zi)
,
and
ρ̂ =
∑
zi
n .
Note that Γ−1 is the inverse gamma function, implemented in R using the igamma
function within the package distr. The EM updates, as indicated by hat symbol, are
made until there is negligible change in the parameter updates, or until a maximum
number of iterations is reached. Initial values of zi, i = 1, 2, ...,n are made by randomly
generating from n independent Bernoulli B(1, 0.5) distributions. After the algorithm
converges, cell i is called ‘highly expressed’ if the estimate of zi, i.e. the estimated
posterior probability of membership of the second component in the mixture model,
zˆi > 0.5 and ‘lowly expressed’ otherwise.
This mixture modelling framework was applied to each scRNA-Seq dataset separ-
ately. The result is a ternary matrix, containing values 0 (no expression), 1 (low ex-
pression) and 2 (high expression), and NA (missing values) with the same number of
rows and columns as the log2CPM matrix. Our algorithm ensured that the mode cor-
responding to the normal component was larger than that of the gamma component,
returning NA values if this was not the case. For each dataset, cell i and gene j the
entries of the ternary matrix is
aij =

0, if yij = 0,
1, if cell i classified to gamma component for gene j,
2, if cell i classified to normal component for gene j, and
NA, if yij > 0 but not enough cells to fit model for gene j.
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Figure 3.3: Contextualising genes to improve mixture modelling. For each gene i we
incorporated log2CPM values of rg other randomly selected genes and fit
the mixture model. This was repeated rr times for each gene, and the major-
ity ternary value of the rr (3 in this example) repetitions taken as the final
ternary value.
Contextualising genes to improve mixture modelling
We considered that there would be a large number of genes for which only a few
cells have non-zero log2CPM values, rendering accurate fitting of the gamma-normal
mixture models difficult. To ameliorate this issue and to ‘borrow strength’ from the
many other genes profiled, we incorporated log2CPM values of rg other randomly
selected genes and performed the EM algorithm. This was repeated rr times for each
gene, and the majority ternary value of the rr repetitions taken as the final ternary
value. We selected the values rg = 10 and rr = 10 for the current analysis. Ties were
dealt with in a conservative manner, that is, that the smaller value was chosen as the
final ternary value for that gene and cell in the case of a tie. This is detailed with a toy
example in Figure 3.3.
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Figure 3.4: Constructing cell-specific coactivation networks. Using some example
data with four cells and five genes, we first construct fully connected
networks for each cell. Following this, edges that appear often (above a
threshold, here 0.5) across the multiple cells (edges 2-3, 2-4, and 3-4) are re-
moved, resulting in the cell-specific coactivation networks considered. Note
for cells 3 and 4 the networks are trivial, i.e. they have no edges.
Identifying transcriptionally active and coactive genes
We supposed that genes with a higher level of expression in given cells are in an active
state, and thus warranted further examination. We determined that genes were ‘active’
in cells if they were classified into the normal component of the mixture model. We
also wanted to characterise which genes tended to be in this ‘active’ state together for
cells, i.e., coactive. In particular we generated a coactivation matrix given by bi{jk} =
1{aij = 2,aik = 2} for i = 1, 2, ...ng, j = 1, 2, ...,ng, and k = 1, 2, ...,n, where ng is the
number of genes, and n is the number of cells. Following this we identify what coactive
pairs of genes were common with known markers of cell types.
3.3.2 Weighting coactive gene networks per cell by uniqueness
Next we attempted to better understand the variation of combinations of pairs of genes
simultaneously expressed among the cells. In particular we wanted to study what
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gene pairs were uniquely coactive among the cells, distinguishing it from the overall
population of cells. Using a measure such as prevalence to weight or filter edges can
highlight different aspects of each cell’s coactivation profile, depending on the focus on
rare or prevalent edges. For instance, weighting towards prevalent edges can highlight
housekeeping or essential genes that are important for the majority the cells profiled.
On the other hand, focussing on rarer or less prevalent edges can highlight sources of
variation in the cell population profiled. In highly heterogeneous cell populations such
as neurons this is of particular interest. We wish to identify to what extent cells differ
from each other in terms of the combinations of genes that are active.
We constructed cell-specific coactivation networks for olfactory related genes (see
Appendix B) by initially building gene-gene networks for each cell, taking the fully
connected network of coactive genes. The number of nodes in this network is equal to
the number of active genes for that cell N, and the number of edges is
(
N
2
)
. In order
to extract biologically meaningful characteristics we next incorporated a weighting per
edge that took into account how often the edge was observed among the entire set of
cell networks. An edge was removed if it was prevalent, that is, if it was observed in
more than 1% of the population of cells, resulting in a network of edges that were more
uniquely coactive in that cell compared to the cell population, detailed in Figure 3.4. To
ensure the robustness of the network characteristics observed, we also perturbed the
threshold for prevalent edges, testing for 0.5%, 1%, 2%, 3%, 4%, and 5%. Following this
we considered the network topology characteristics of each cell’s coactivation network.
3.4 evaluation using application to neuronal datasets
In this section we evaluate our approaches on multiple mouse neuronal datasets, and
in particular three OSN datasets. We present results related to the mixture modelling
framework in Section 3.4.1 and evaluate its capacity to standardise between datasets in
Section 3.4.2. We evaluate the identification of OSN maturity gene markers in Section
3.4.3 using existing biological information and finally in Section 3.4.4 we present results
on estimated cell-specific coactivation networks.
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3.4.1 Gamma-normal mixture is versatile for a number of transcriptional profiles
We found that using a gamma-normal mixture model was suitable for accommodat-
ing the different empirical densities of the neuronal scRNA-Seq data. Figure 3.2 shows
histograms of log2CPM values for all genes and cells for each dataset, with zeroes re-
moved (barplot below each histogram shows the proportion of zeroes in each dataset).
We found that while some datasets tended to have lower percentage of zeroes (e.g.
Li et al. (2015a) and Lovatt et al. (2014)) resulting in a peak close to zero, the gamma-
normal model was able to fit even this aspect of the data well.
However, since genes can have different dynamic ranges due to various technical
effects (e.g. amplification or GC content bias), it is more suitable to estimate paramet-
ers of the gamma-normal mixture on a per-gene basis. Figure 3.5 shows histograms
of log2CPM values for genes ACTB, NCAM2, ACSM4, NRP1, OLFR726, for datasets
Hanchate et al. (2015), Saraiva et al. (2015) and Tan et al. (2015), as well as the estimated
gamma-normal mixture model densities. These three datasets were chosen as they all
profile OSNs, allowing for more direct comparisons without having to account for spe-
cific cell-type differences. The modelling framework identifies when the gene is highly
expressed for all cells (ACTB a known housekeeping gene), as well as reasonable estim-
ates for mixtures of lowly and highly expressed genes. However, when there are too
few cells with non-zero log2CPM values then the modelling framework is no longer
reliable and can break down, for example the gene OLFR726 for Tan et al. (2015) there
are only 2 cells with non-zero log2CPM values. We found that contextualising genes,
described in Figure 3.3, enabled for these cells to be classified more accurately by in-
cluding more data points into the mixture model. Contextualising genes resulted in
removal of missing values due to too few data points and further increased the differ-
ence between log2CPM values for genes and cells classified as 1 (lowly expressed) and
2 (highly expressed) (Figure B.1).
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Figure 3.5: Histograms of log2CPM values of cells for particular genes (ACTB,
NCAM2, ACSM4, NRP1, OLFR726) for three datasets (Hanchate et al., 2015;
Saraiva et al., 2015; Tan et al., 2015). Black lines represent the mixture model
and the other two blue and red coloured lines represent the gamma and
normal mixture components respectively. Performance of the mixture mod-
elling framework can break down with few non-zero cells.
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3.4.2 Incorporating ternary data slightly improves read depth effects within datasets
Next we considered what impact the total depth of sequencing had on the detection
of genes. We found that in general as read depth tends to increase, the number of non-
zero count genes also tends to increase (Figure B.2). However it seems that this effect is
strongest when read depth is relatively low. This is important since different datasets
(e.g. Usoskin et al. (2014)) have a very large dynamic range along the total read depth
of the cells, and thus the number of identified genes would be biased. This also hints
towards how deeply one should sequence the mRNA within a cell to be confident of
capturing enough read counts for the data to be of further use in the analysis. We
found after generating ternary matrices by fitting gene-wise gamma-normal mixture
models, and considering the set of genes related to olfactory GO terms (described in
Appendix B) that this observed relationship between read depth and number of highly
expressed genes was slightly diminished (Figure 3.6). However the effect of read depth
and number of active genes persists for some datasets, most notably that related to
Usoskin et al. (2014). Figure B.3 displays the number of non-zero count genes against
number of active genes, showing that the largest change occurs with data from Lovatt
et al. (2014), indicated by the fitted line.
From this point on we focused on the OSN datasets (Hanchate et al., 2015; Saraiva
et al., 2015; Tan et al., 2015) and on genes related to the olfactory system as curated
from GO, as this allowed us to combine and analyse data sets within the context of
consistent cell types. We removed cells from the Saraiva et al. (2015) dataset that were
removed in the original analysis, due to various technical effects such as cell clumping
or breakage of cells (Saraiva et al., 2015). Our interest lies in only active genes, so
we converted the ternary matrices to binary matrices by setting values of 0 or 1 as 0,
and values of 2 as 1. Thus the binary matrix represented 0 for no or low expression
state, and 1 for a high or active expression state. In order to ensure that this data
transformation led to increased comparability, or effective standardisation, of the three
transformed datasets, we compared the binary matrix to the corresponding matrix
of log2CPM values in terms of classification performance. Figure 3.7 (left) shows the
principal components analysis (PCA) for both the binary and continuous data, and we
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Figure 3.6: Scatterplots of total read depth versus number of non-zero log2CPM val-
ues (top left) and (middle left) number of active genes using genes related
to olfactory system. Boxplots (top right, middle right, respectively) are of
the number of non-zero log2CPM values and number of active genes us-
ing genes related to the olfactory system respectively, split by dataset. The
last boxplot (bottom left) is of total read depth of cells from various data-
sets. We observe some relationship between total read depth and number
of non-zero genes (top left), which is slightly diminished when comparing
total read depth to the number of active genes (middle left) for datasets
with lower total read depth.
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observe greater overlap of cells among the binary data than the continuous data. The
hierarchical clustered heatmap of binary values in Figure 3.7 (right) shows the cells,
coloured by dataset, are well mixed between datasets, using Jaccard distance as the
distance metric. In order to quantify what we observe in the figures, we considered how
cells can be attributed to their original dataset via k-nearest neighbours classification.
Since these cells belong to the same cell-type, we can assume that differences between
these cells arise from non-biological factors such as technical differences. Thus if we
observe a lower classification accuracy of a cell to its original dataset label, then we
can conclude that the transformation of the data results in increased comparability
of the cells across the individual datasets. Indeed, performing a k-nearest neighbours
classification on the originating dataset, the leave-one-out cross validation accuracy is
diminished for the binary data, 66.7%, than the continuous, 71.4%, further assuring us
that dataset specific effects are largely removed by transforming the data into binary
active/non-active states.
3.4.3 Evaluating coactivation with known maturity markers
Next we aimed to understand which genes are markers for maturity of OSNs. We ap-
plied this test in three cases: separately to the Hanchate et al. (2015) dataset and Tan et al.
(2015) dataset, and to the concatenated dataset of Tan et al. (2015) and Hanchate et al.
(2015). Note that we did not further consider the Saraiva et al. (2015) dataset as their
experimental protocol selected for only mature neurons, that is those cells expressing
OMP. A number of transcriptional markers are known for cell maturity and immatur-
ity, such as OMP and GAP43, respectively (Kream and Margolis, 1984; Verhaagen et al.,
1990; Anders et al., 2015; Margolis et al., 1991; Tan et al., 2015). Using our estimates
of transcriptionally active genes and cells, we considered coactivation of genes with
these markers. We defined cells that were active for OMP and not for GAP43 as mature
cells, and those active for GAP43 and not for OMP as immature cells, and tested for
coactivation among all genes in the transcriptome via Fisher’s exact test, taking note
of the gene in which coactivation occurred (coactivating with OMP suggests a mature
marker or coactivating with GAP43 suggests immature marker), thereby identifying if
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Figure 3.7: Principal components scores (PC1 vs PC2 and PC2 vs PC3) for binary val-
ues (right, top two graphs) and continuous log2CPM values (left, bottom
two graphs) for cells from Hanchate et al. (2015) (red), Saraiva et al. (2015)
(green) and Tan et al. (2015) (blue). Heatmap of olfactory system genes and
cells from Hanchate et al. (2015) (red bars), Saraiva et al. (2015) (green bars)
and Tan et al. (2015) (blue bars), using binary values (black for ‘active’ and
light grey for ‘inactive’). Hierarchical clustering was performed using the
Jaccard (binary) distance metric. Only cells from Saraiva et al. (2015) dataset
that passed the quality control were included here.
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the tested gene was related positively toward maturity of immaturity. Cells that were
either active for both GAP43 and OMP or not active for either were not included for
further testing of coactivation, resulting in 107 OMP active cells, 51 GAP43 cells, and
78 cells that were neither. Genes with Bonferroni-corrected p-values below 0.01 were
considered as significantly coactivated with either OMP or GAP43.
In order to evaluate these identified marker genes, we curated lists of genes that
have previous evidence as markers for mature or immature OSNs. We used a set of
8 mature-specific and 10 immature-specific marker genes from Tan et al. (2015) and a
set of 691 mature-specific and 847 immature-specific marker genes from Nickell et al.
(2012), resulting in a combined list of 692 mature-specific and 851 immature-specific
marker gene names, taking into account that multiple gene name aliases may exist.
This list of genes stems from literature-based and gene expression analysis and we note
that it may not be exhaustive, thus cannot be treated as a gold-standard positive set of
genes. Comparison of our analyses of the two individual and merged datasets with the
‘reference’ gene list showed 95 of the 152 (62.5%) Tan et al. (2015), 27 of the 34 (79.4%)
Hanchate et al. (2015), and 149 of the 245 (60.8%) merged marker genes appeared in
the reference mature list. We found that 30 genes were common between the Tan et al.
(2015) (19.7%) and Hanchate et al. (2015) (88.2%) mature gene lists. We also found that
45 of the 73 (61.6%) Tan et al. (2015), 11 of the 27 (40.7%) Hanchate et al. (2015), and 63 of
the 120 (52.5%) merged marker genes appeared in with the reference immature list. We
found that 12 genes were common between the Tan et al. (2015) (16.4%) and Hanchate
et al. (2015) (44.4%) immature gene lists. There was only one instance in which a gene
identified as a mature marker was listed in the set of immature-specific marker genes
or vice versa, in which the gene TPM3 appears in the merged mature marker gene list
but appears in the literature based immature markers list, no other identified mature
or immature gene was in the immature or mature respectively list.
Our analysis of the merged data sets identified 40 candidate genes that co-activated
with OMP but were not found to coactivate with OMP when the individual datasets
were analysed alone (Table B.1 and Table B.2). Of these 40 genes, three (RTP1, RTP2,
PDLIM1) are expressed in mature OSNs (Saito et al., 2004; Tietjen et al., 2005). RTP1 and
RTP2 encode for proteins that facilitate the transport of odorant receptors to the mem-
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brane surface, a critical component for functional maturation of OSNs. The function
of PDLIM1 in mature OSNs is unknown. NXPH3 has been shown to be expressed in
OSNs in a cAMP dependent manner (Imai et al., 2006). Of the remaining 36 genes, none
have been studied in the olfactory system. However, four are involved in ciliogenesis
(CCDC114), synapse formation (NAPA), and excitation (CACNA1H, CAR2), consistent
with a role in later stages of neuronal development. An additional seven have been
shown to regulate axon guidance (ARHGEF28, BOC), neurite outgrowth (SDC3), neur-
onal morphology (TPM3), and differentiation (NFATC1, CTSB, CEND1). No clear asso-
ciation with neuronal specific function or expression could be easily inferred for the re-
maining 25 genes (Table B.2), however, none are known markers for neural immaturity.
Our findings support the utility of the merged mixed model approach for enhancing
the detection of coactivated genes with merged scRNA-Seq data sets. Our approach
identified 40 potential new markers, at least three of which are already known to be
expressed in mature OSNs.
3.4.4 Cell-specific coactivation networks reveal network characteristics related to cell maturity
We generated cell specific coactivation networks, by weighting edges on how unusually
they appear in the dataset. Specifically, we included edges between two coactive genes
if they appeared in less than 1% of the cell population, effectively weighting towards
coactivation events that are rarely present than prevalent coactivating events. Upon ex-
amining some of these individual cell networks, it appeared that some had a very clear
hub-partner topology, characterised by many partners leading to one or two nodes
and no other connections (Figure 3.8 bottom row), and others were more dense in the
number of connections between different nodes (Figure 3.8 top row). This suggests
that for some cells, a single gene is uniquely activating, and thus coactivation occurs
with the other genes that may be active in more cells, whereas for others there are a
number of genes appearing uniquely, lending itself to a more densely connected net-
work. In order to identify possible reasons for these different topologies, we considered
comparing the centralisation measures between cells that are mature OSNs and imma-
ture OSNs. Centralisation is a measure of how central connections are towards some
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Figure 3.8: Examples of individual cell networks for immature neurons (top row)
and mature neurons (bottom row). Violin plot shows centralisation meas-
ures for immature and mature cells, with mature cell networks having a
higher centralisation than immature overall (P<0.02 two-sample t-test) Col-
our indicates the dataset the cell originated from (red - (Hanchate et al.,
2015), green - (Saraiva et al., 2015), and blue - (Tan et al., 2015)). Violin plot
of centralisation scores for immature and mature neurons.
nodes, and are higher in networks with hub-partner topology (Freeman, 1978), a ‘star’
network with all edges connecting towards a single hub node has the maximum cent-
ralisation score of 1. Centralisation of a network G with |V | nodes, C(G), is calculated
by first calculating the sum of the difference of each node’s degree (CD(vi)) and that
of the most connected node v∗, and then divided by the highest possible theoretical
centrality (H),
C(G) =
1
H
|V |∑
i=1
(CD(v∗) −CD(vi)) ,
where
H =
|V |−1∑
i=1
((|V |− 1) − 1) = (|V |− 1)(|V |− 2).
As described earlier, we identified immature OSNs as those cells that were active for
the gene GAP43 and inactive for OMP, and mature OSNs as those cells that were
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active for OMP and inactive for GAP43. We considered only non-trivial networks with
at least 5 nodes, resulting in 111 individual mature cell networks and 39 individual
immature cell networks. We found that mature cell networks tend to be more central
than immature cell networks (p-value<0.01, two-sided two-sample t-test). To ensure
robustness of this result to choice of thresholds, we also compared networks with only
edges appearing in less than 0.5%, 1%, 2%, 3%, 4%, and 5% of the cell population. In
all cases we observed a significant difference in centralisation between the two groups
(p-values 0.012, 0.013, 0.0032, 0.003, 0.0011, and 0.00046 respectively, two-sided two-
sample t-test). Some representative cells from these groups are shown in Figure 3.8.
The entire set of non-trivial networks is shown in Figures B.4-B.12.
3.5 discussion
In this chapter we propose a method to identify transcriptionally active (highly ex-
pressed) gene patterns in scRNA-Seq data. This was achieved by employing a gamma-
normal mixture modelling approach. This gene expression classification further en-
abled key observations in neuronal cell quality control, and facilitated examination of
maturity markers with improved identification in combining datasets. In addition, we
developed cell-specific coactivation networks that allowed determination of topological
features and relating them to specific features of the cells.
Some discussion as to what causes the apparent bimodal distribution of scRNA-
Seq data has attributed these highly expressed genes to transcriptional bursting (Suter
et al., 2011), referring to very rapid production of RNA occurring in bursts, owing to
the stochastic nature of transcription in the cell. Indeed, transcriptional bursting has
been explored both theoretically (Kumar et al., 2015), within cell-line studies (Raj et al.,
2006), and in the context of scRNA-Seq data (Kim and Marioni, 2013). Our mixture
modelling framework enables identification of genes for which the cell is possibly
undergoing transcriptional bursting or is highly expressed, as those that were deemed
‘active’ throughout this chapter, and thus potentially can be used to analyse bursting
states given a suitable experimental protocol. One issue is the parametric nature of
the mixture modelling approach. It may be the case that the gamma-gamma mixture
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model is similarly flexible to the gamma-normal mixture model in describing the data.
Also one may not bother with parametric description of the data and instead fit some
mixture of non-parametric concave densities for even more flexibility.
Potential limitations of the method introduced in this chapter is the treatment of zero
counts. In the case where there are many false positive reads, that is, reads mapped
to a gene when in fact there is no underlying transcription occurring, the error may
propagate and cells be classified as lowly or less likely highly expressed. A strategy
for dealing with this issue may be to incorporate a third component into the gamma-
normal mixture model, where the third component has a very high probability density
at zero, but also incorporates a non-zero probability for non-zero values. Of course, this
requires that the proportion of non-zero values can be somehow estimated. However, in
this chapter our key observations stemmed from focusing specifically on active genes,
and potential issues associated with false positive reads are negligible in this particular
setting.
Additional methodological developments are needed for datasets and genes that
do not have a clear bimodal distribution of expression values. These are cells with
very little to no highly active genes and did not have enough cells to accurately fit
the gamma-normal mixture model, e.g. Figure 3.5 for OLFR726. Given a suitable con-
tinuous normalisation approach, this issue of not enough cells can be ameliorated by
simply combining the cells into one large merged dataset. This of course is dependent
on a reliable cross-dataset normalisation strategy. Methods on batch correction (John-
son et al., 2007) and normalisation of bulk RNA-Seq (Risso et al., 2014; Love et al., 2014;
Robinson and Oshlack, 2010) data exist, but it is not yet clear how applicable these
approaches are given the unique characteristics of scRNA-Seq such as the abundance
of zero values, with strides in effective normalisation of scRNA-Seq data actively de-
veloping (L. Lun et al., 2016).
Our definition of cell-specific coactivation networks does not rely on existing net-
works and offers the possibility of uncovering novel aspects of these networks, identify-
ing genes that may be ‘transcriptionally bursting’ concurrently, further leading towards
uncovering the dynamics of transcription at the single cell level. Our implementation in
this chapter has focussed on genes specifically related to olfaction but can certainly be
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expanded to the entire transcriptome. Alternatively, these coactivation measures could
be overlaid on existing networks such as PPI networks or an existing gene regulatory
network, and could thereby identify aspects of the existing networks that are worthy
of further consideration, akin to identifying ‘network hotspots’. Furthermore, as statist-
ical research continues in analysing data arising from such technologies along with the
specific characteristics described in this chapter such as zero inflation and bimodality,
we will move towards estimating gene regulatory networks taking these distributions
into account, leading to more accurate representations of the transcriptional processes
occurring in each cell. We found that our observed cell-specific coactivation networks
tended to have similar number of nodes and edges, with hub nodes typically being
olfactory receptor genes, highlighting their unique expression over the population of
cells, as opposed to homogeneous expression of all olfactory receptor genes across all
cells.
Using methods to identify active genes and coactive gene pairs within cells, we have
been able to identify gene markers for OSN maturity across multiple datasets, and to
observe characteristics of cell-specific coactivation networks weighted by uniqueness.
This unique way of characterising scRNA-Seq data has enabled interesting observa-
tions and future applications to other types of scRNA-Seq will be of interest.
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Genes and proteins function as a biological system rather than in isolation, and in
cancers the operation of these systems may be disrupted. Identifying the individual
genes and pathways, and their connection to other genes and pathways involved in
this disruption is a crucial step in understanding the processes involved in cancer
formation and spread. Understanding how these gene and protein networks function
in cancers can also lead to identification of potential therapeutic targets, and thereby
impact on treatment of patients. The genetic basis behind the growth of cancers is mani-
fested fundamentally through mutations in the DNA within tumour cells, impacting
gene expression levels potentially leading to phenotypic changes in the cell via protein
translation or other mechanisms.
High throughput sequencing technologies have facilitated the large scale profiling
of the tumour DNA and RNA, capturing a snapshot of the DNA sequence changes
and transcriptional expression within the tissue. With the availability of such data we
are equipped to investigate the global cancer network and its properties. The goal is to
understand and characterise the complex relationships between mutations in the DNA
and other aspects of the tumour such as gene transcriptional expression.
In this chapter we develop two novel approaches to further elucidate the relation-
ship between gene expression and somatic mutations in cancers with matched and
unmatched data. First, we consider a linear modelling approach to relate somatic muta-
tions and gene expression differences in the context of protein-protein interaction (PPI)
networks when the associated samples are matched. We also developed an interactive
visualisation tool to investigate the directed networks generated from this analysis.
Second, we consider the relationship between somatic mutation driver gene scores
with gene coexpression disturbances between good and poor survival groups, noting
that this approach is suitable for integrating datasets where samples are unmatched.
4.1 biological data
Key biological data involved arises from high throughput sequencing technologies,
namely whole exome sequencing (WES) and RNA sequencing (RNA-Seq) described
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Figure 4.1: Mutation analogy with words. Different types of mutations, and the effect
they have on the genetic ‘code’. Words here are analogous to the three nuc-
leotide codons that translate into amino acids. Point mutations change a
single nucleotide, which can be either synonymous (due to redundancy of
the amino acid code) or nonsynonymous (leading to a change in the amino
acid). Inversions reverse the order of a sequence of any length. Deletions
are the loss of any number of nucleotides, leading to loss of some codons
and/or changes in the following codon sequence. Similar to deletions, inser-
tions insert any number of nucleotides, also potentially leading to changes
in the following codon sequence. Translocations are changes in the order of
sequences of nucleotides, leading to different protein structures as well as
codon changes. In reality, many of these types of mutations may be present,
which can lead to catastrophic changes from the original DNA sequence.
in more detail in Section 1.2. We describe these data sources in the context of the
cancer study in this section. Data in this chapter predominantly stems from TCGA, as
described in Section 1.3.2 and described in more detail within this chapter.
4.1.1 Mutation data
In cancers, changes to the DNA sequence occur and lead to malignancy, described well
by the hallmarks of cancer (Hanahan and Weinberg, 2011). This leads to catastrophic
changes to the cell and its corresponding environment, leading to tumour formation
and spread. A number of events occur that lead to these hallmarks, such as resisting
cell death, fast proliferation, angiogenesis (formation of blood vessels), enabling replic-
ative immortality, to name a few. Somatic mutations can differ however in terms of the
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Figure 4.2: Possible mutation locations and types in a transcript. The locations where
somatic mutations can occur in a DNA transcript sequence as well as the
type of mutation that can occur within each area. Blue hexagon is transcrip-
tion factor (TF) binding region, dotted lines represent intergenic regions,
blue unfilled blocks are untranslated regions (UTR), blue filled blocks are
exonic regions, and blue lines represent intronic regions. Possible mutations
are colour coded on potentially low moderate of high impact on the result-
ing transcript and possible protein product. Below this is also larger scale
genomic changes such as copy number variation, inversions and deletions.
downstream effect the change has on the corresponding RNA sequence. An analogy is
shown in Figure 4.1. Some mutations tend to be more damaging than others, leading
to the notion of ‘driver’ and ‘passenger’ mutations (Stratton et al., 2009). It is believed
that following accumulation of driver mutations, repair mechanisms no longer func-
tion correctly, leading to a host of other mutations occurring, for instance mutations in
the BRAF gene in melanoma (Ascierto et al., 2012) or APC in gastrointestinal tumours
(Minde et al., 2011). We can characterise mutations based on various properties (Fig-
ure 4.2), further discussed in the later subsection. Note that consideration of germline
mutations is outside the scope of this thesis, as there is a large body of work related to
studying genetic variation in relation to heritability and susceptibility to cancers.
Identification of somatic mutations is obtained from high throughput sequencing
of the DNA, either using just the exonic regions (WES) or the entire genome (whole
genome sequencing WGS), of the tumour tissue and compared to either surrounding
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normal tissue or that of the blood. Differences in nucleotides between the tumour and
normal are identified as somatic mutations. These can be in the form of single nucle-
otide variants (SNVs) or in small insertions or deletions of sequences of nucleotides
(INDELs), as well as larger scale genomic rearrangements such as copy number vari-
ation (CNVs), and large gene insertions and deletions. The overarching questions one
can answer with data associated with somatic mutations are
• what are the most prevalent mutations and genes associated; and
• what function do these mutations play?
Various approaches have been suggested to do so, all utilising various characteristics
associated with mutated genes of interest. For instance, the idea of mutually exclusive
mutations are likely to be driver mutations (Ciriello et al., 2012), or those that are
more mutated compared to a background mutation rate (Lawrence et al., 2013). It may
be useful to assign scores to mutations based on certain criteria, as described later in
Section 4.3.1 (Gnad et al., 2013; Frousios et al., 2013; Dees et al., 2012). Somatic mutations
have many downstream impacts, some depicted in Figure 4.2, such as synonymous (no
effect on protein) and non-synonymous (some effect on protein) mutations, among a
host of others not necessary in the exonic part of the transcript sequence.
4.1.2 Gene expression data
As outlined in the Introduction, according to the central dogma of molecular biology,
genetic information flows from the DNA to the RNA. In the specific case of cancer,
the DNA harbours mutations, which can flow on to changes in the RNA sequence as
well as the protein sequence. Furthermore, not only the sequence of the RNA may be
changed due to these mutations, but the amount of RNA present altogether, due to
various mechanisms such as premature decay of the RNA. The key quantity related
to RNA we examine in this chapter is gene expression abundance information, and
how changes in these relates to the somatic mutations in cancer. As described in the
Introduction, mapped sequence reads can be counted per gene and used to estimate
the gene expression abundance information.
The cancer gene expression data presented in this chapter is that of the tumour itself,
and the gene expression data of the corresponding normal tissue is not available.
4.2 pacmen : integrative framework to determine cancer network re-
lationships for matched mutation and gene expression data .
In this section, we describe a novel approach to determine cancer network relationships
using matched mutation and gene expression data. We applied this framework to 19
cancer datasets from TCGA and integrated the results into an R Shiny interface named
PAn Cancer Mutation Expression Networks (PACMEN), allowing dynamic visualisa-
tion of the observed mutation expression networks.
In recent years, pan-cancer network research has come to the forefront with the use
of large-scale matrix summarisation techniques such as non-negative matrix factorisa-
tion (NMF) and clustering to identify commonalities across different cancers (Jia et al.,
2014; Hofree et al., 2013). Leiserson et al. (2014) conducted a pan-cancer analysis by con-
sidering the mutations over multiple cancers and implementing the HotNet2 algorithm
to identify significantly mutated subnetworks. More recently methods have aimed to
incorporate both gene expression and mutation information in a network setting to
identify genes and networks of interest. For example, in a direct interrogation of a
dozen genes harbouring somatic mutations, Gerstung et al. (2015) examined the muta-
tion and expression network characteristics in myelodysplastic syndromes, leading to
improved accuracy in the prediction of patient outcome. Similar studies have also been
conducted in certain disease settings (Bashashati et al., 2013). On a larger scale, more
suited to high-throughput studies, DriverNet (Bashashati et al., 2012) identifies a set of
driver genes by building bipartite graphs between mutated genes and genes with outly-
ing gene expression values. Similar algorithms make use of a combination of mutation,
gene expression and external network information (Hou and Ma, 2014; Jia and Zhao,
2014; Paull et al., 2013).
However, most of these algorithms do not analyse the data in a direct manner, and
do not enable incorporation of sample-specific information such as prognosis among
other clinical variables. To this end, we introduce a framework that performs direct
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testing, accounting for such information via covariates introduced in linear models. We
build directed networks resulting from differing gene expression levels by partitioning
via mutation, and build bipartite graphs between mutated genes and pathways for
which pathways are significantly affected according to mutation status in samples. This
enables us to elucidate the potential mutational basis behind gene expression changes,
on a single gene and pathway basis.
4.2.1 Data and testing framework
There are three main data components in this framework, mutation information stem-
ming from WES, gene expression data stemming from RNA-Seq and PPI information
from a multitude of sources, described in more detail below. The entire framework is
summarised in Figure 4.3.
mutation : Mutation information was downloaded from TCGA data portal
(https://tcga-data.nci.nih.gov/tcga/) between 14 November 2013 and 9 July 2015, lis-
ted in Appendix Table C.1. For each cancer, nonsilent mutations were identified from
the full list of mutations, using the ‘Variant_Classification’ parameter in those datasets.
For each cancer dataset analysed, a binary nonsilent mutation incidence matrix M was
formed by setting
Mij = 1at least 1 nonsilent mutation in gene i and sample j
for gene i = 1, 2, . . . , I and sample j = 1, 2, . . . , J, where 1 is the indicator function.
gene expression : Gene expression and clinical information was downloaded
directly into R using the R package AnnotationHub (Morgan et al., 2016) obtaining data
from GEO submission ID GSE62944. The gene expression data contained raw RNA-Seq
read counts obtained using the package Rsubread (Liao et al., 2013). We converted the
RNA-Seq counts to log2CPM (counts per million) via the voom function in the limma
package. For each cancer dataset analysed, a continuous gene expression matrix Y was
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Figure 4.3: Overview of the PACMEN Method. A binary matrix of nonsilent muta-
tions are filtered based on a minimum percentage mutation rate, and con-
nectedness in the UPPI network. Among random subsets of the samples,
linear models are fitted using these binary vectors to test for differential
gene expression among the neighbours in the UPPI network. Then directed
edges are drawn among repeatedly mutated genes and the significantly DE
genes. Edges point from mutated genes to DE genes, and are denoted as
tail and head nodes respectively.
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formed where Yik indicates the expression level in sample i = 1, 2, . . . , I and gene
k = 1, 2, . . . ,K.
Sets of identified somatic mutations and gene expression data originated from TCGA
as described. A sample was retained in a cancer cohort if both mutation and gene
expression information was available. A total number of 4,443 tumour samples were
analysed from 19 different cancers, listed in Table 4.1. Sample sizes ranged from 66
to 665, with a median of 207 samples. To enable downstream differential expression
(DE) analysis, genes with nonsilent mutations for fewer than 3 samples were removed,
resulting in between 26 and 18,190 genes with mutations, with a median of 4,353 genes.
Lowly expressed genes were removed, i.e. those with fewer than 20 mapped reads for
at least 50% of the samples. This resulted in numbers of genes with gene expression
information ranging from 13,660 to 16,410, with a median of 15,670 genes.
ppi information : A union PPI network, denoted UPPI, was built by construct-
ing the union of the five PPI networks listed in Table 4.2, with 68,832 edges shared
among 12,237 nodes. This network effectively limits the search space in testing DE with
respect to mutation, allowing statistically significant and potentially more biologically
relevant relationships to be observed. It is entirely feasible that genes’ expression may
be associated with mutations that are multiple steps away in the network, thus we also
considered a larger search space named UPPI2, defined by drawing edges between
nodes that share are least one interacting partner.
We compared UPPI and UPPI2 with an existing consolidation of PPI networks,
namely HIPPIE (Schaefer et al., 2012), using the high-confidence cut-off of 0.68 as pre-
viously conducted (Zhang et al., 2015), and found that UPPI and HIPPIE share 4,450
nodes and 7,837 edges, as shown in Figure C.1. Mutated genes were tested for DE
among their neighbours within the UPPI network.
Selecting genes for testing
For each cancer we selected genes that were in the top 10% most prevalent nonsilent
mutated genes by calculating the 0.9 quantile of nonsilent mutation counts over all
genes. Genes were selected to test for DE if the number of samples with nonsilent
4.2 pacmen 71
Table 4.1: Cancer data downloaded from TCGA. The number of samples, mutated
genes following filtering, number of mutated genes for further analysis, and
number of non-lowly expressed genes.
TCGA
Name
Full Name Samples
Genes
with
mutations
Selected
mutated
genes
Genes with
measured
expression
BLCA Bladder urothelial carcinoma 208 7,199 356 15,515
BRCA Breast invasive carcinoma 665 6,278 249 15,864
COAD Colon adenocarcinoma 207 9,382 470 15,253
GBM Glioblastoma multiforme 146 378 16 15,991
HNSC Head and neck squamous
cell carcinoma
382 7,889 386 15,465
KICH Kidney chromophobe 66 36 2 15,253
KIRC Kidney renal clear
cell carcinoma
210 2,938 128 16,061
KIRP Kidney renal papillary
cell carcinoma
113 363 18 15,671
LAML Acute myeloid leukemia 102 26 3 13,661
LGG Brain lower grade glioma 393 2,487 113 16,187
LIHC Liver hepatocellular carcinoma 159 18,191 690 14,665
LUAD Lung adenocarcinoma 439 12,467 635 15,923
LUSC Lung squamous cell carcinoma 177 6,123 312 16,323
OV
Ovarian serous
cystadenocarcinoma 77 53 2 16,409
PRAD Prostate adenocarcinoma 318 1,335 68 15,957
READ Rectum adenocarcinoma 80 1,456 72 15,479
SKCM Skin cutaneous melanoma 325 13,034 663 15,218
STAD Stomach adenocarcinoma 134 4,353 223 16,155
UCEC Uterine corpus endometrial
carcinoma
242 14,139 625 14,517
mutations were above this value. The use of this measure as opposed to an absolute
threshold was adopted in order to account for the differing levels of overall mutation
both between and within cancers, as shown in Figure C.2.
To enable investigation of less prevalent mutations in highly interactive genes, highly
connected genes in the UPPI network were included in the testing set. A gene was
included if it had over 250 partners in the network (degree distribution shown in Figure
C.3, of which there are 17 such genes. We did the same for the HIPPIE network, of
which there are 12 such highly connected genes.
Single gene network edge building
For each cancer dataset and mutated gene, samples were partitioned depending on the
mutation status of the gene, followed by a DE analysis (Ritchie et al., 2015) among the
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Table 4.2: PPI information The number of nodes and edges in each of the PPI networks
with citations. UPPI is the network built from the union of the five networks,
and UPPI2 built by taking the second order interactions in UPPI.
PPI Number of Nodes Number of Edges Citation
BioGRID 4094 8098 (Breitkreutz et al., 2007)
Human Interactome
(HI-II-14) 4303 13427 (Rolland et al., 2014)
Human Protein
Reference Database
(HPRD)
9453 36867 (Keshava Prasad et al., 2009)
iRefWeb 7256 21049 (Turner et al., 2010)
MetaCore 5009 16202 (Ekins et al., 2007)
HIPPIE 9872 47517 (Schaefer et al., 2012)
Union PPI 12237 68832
PPI2 12237 2504363
gene’s neighbours in UPPI. In particular, let Mij be the binary matrix for sample i and
mutated gene j as described earlier. For each mutated gene j and UPPI partner k, the
linear model was formed for sample i
Yik = αjk +βjkMij + ijk (4.1)
where Yik is the expression level of sample i and gene k, equal to αjk for samples
with no mutation in gene j and αjk + βjk for samples with a mutation in gene j,
and ijk is random noise. Thus βjk captures the average expression level difference
between samples with and without the mutation and thus measures the effect of the
mutation on the gene’s expression. A test of differential expression corresponds to
addressing the null hypothesis H0 : βjk = 0 vs. βjk 6= 0. This was implemented using
the limma R package, employing the empirical Bayes procedure to perform moderated
t-tests. Since the hypothesis test is repeated across mutated genes and their partners
in UPPI, a multiple comparison correction is required, wherein the false discovery rate
(FDR) is controlled at a level of 0.1. The FDR transformation was carried out within a
gene, within a cancer. For each gene identified as significantly DE, a directed edge is
drawn from the mutated genes for which the samples are partitioned to the DE gene.
Repeatedly conducting this over the set of mutated genes for testing builds a directed
network. As such we term mutated genes as ‘head’ nodes in the network, and the DE
genes as ‘tail’ nodes. Certainly genes can be both head and tail nodes simultaneously.
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We note that in this setting, due to the interconnectedness and lack of independ-
ence between DE tests, it is difficult to assign meaning in terms of evidence of an
alternate hypothesis using the p-values. In this setting we treat the FDR adjusted val-
ues as a score, thus allowing them to prioritise edges to guide our analysis. It must
also be noted that this model does not intend to identify causal relationships between
mutated genes and DE genes. The direction of arrows drawn in the network are to
indicate which genes are mutated and which exhibit significant differential expression.
An overview of this method is shown in Figure 4.3.
Pathway network edge building
Pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Ogata et al.,
1999) were downloaded using the KEGG.db package (Carlson, 2016) in R and Entrez
IDs were converted to HUGO Gene Nomenclature Committee (HGNC) gene symbols.
Gene sets with fewer than five genes were removed. KEGG pathways were tested for
differential gene set expression using the WilcoxGST function within the limma package
according to the mutation status of the gene being tested. This is a competitive gene
set test, with documented reliance on gene-gene correlations that may falsely inflate
the false discovery rate (Efron and Tibshirani, 2007). As such, a significance threshold
of a FDR below 0.1 was used in order to build the edges of a bipartite graph for each
cancer. An overview of this method is shown in Figure C.4.
4.2.2 Evaluation of networks
External databases and other algorithms
A number of external databases were used as known cancer-related gene lists, detailed
in Table 4.3. These enabled evaluation of the networks in terms of potential biolo-
gical importance and interpretability. Furthermore we implemented the DriverNet al-
gorithm (Bashashati et al., 2012) using default parameters on the same gene expression
and mutation matrices using the UPPI network, and considered the list of ‘drivers’
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Table 4.3: Known cancer gene databases. Details of known cancer gene databases, in-
cluding the number of genes.
Abbreviation Full Name Number of Genes Citation
NCG 4.0 Network of Cancer Genes 2,000 (An et al., 2014)
CGC Cancer Gene Census 571 (Futreal et al., 2004)
COSMIC Catalogue of Somatic
Mutations in Cancer
28,414 (Forbes et al., 2014)
Drugbank 1,586 (Law et al., 2014)
identified as another means of assessing the concordance of the present approach with
others.
Comparing observed networks to randomly permuted networks
To determine the amount of biological signal within the observed networks, a set of
randomly permuted networks were built. Generating this randomly permuted set al-
lowed for measurement of significance of the observed networks via calculation of
empirical p-values. This was done by randomly reassigning the gene and sample la-
bels in the mutation and gene expression matrices a total of 1,000 times for the single-
gene approach and 100 times for the pathway based approach, allowing calculation
of empirical p-values as small as 0.001 and 0.01 respectively. The external information
sources, i.e. UPPI network and KEGG pathways respectively, remained unaltered for
each iteration.
Visualisation of networks
The generated mutation-expression networks were visualised using the R package
igraph (Csardi and Nepusz, 2006), in which edge colours signified either up or down-
regulation in the single gene setting. In the case of the pathway setting, the mutation-
expression network is in fact a bipartite graph and was visualised as such.
Pan-cancer comparisons
Pan-cancer comparisons were carried out by considering the concordance of the nodes
of the generated mutation-expression networks per cancer. This was done by consid-
ering separately the head and tail nodes of the networks. As illustrated in Figure 4.3,
head nodes refer to those in which DE is observed among samples mutated in their
4.2 pacmen 75
corresponding tail nodes. A measure of co-occurrence and exclusiveness of sets is the
Jaccard distance, defined as
dJ(A,B) =
|A∪B|− |A∩B|
|A∪B| (4.2)
for setsA and B (Levandowsky and Winter, 1971). If the two sets are mutually exclusive
then the Jaccard distance is 1, and if the sets completely overlap, that is A ∪ B =
A ∩ B, then the Jaccard distance is 0. The Jaccard distance was calculated for the sets
of tail nodes among cancers as well as head nodes. Furthermore, a comparison of the
entire networks was done by taking the pairwise Jaccard distances of all nodes in each
generated mutation-expression network.
We also considered the mean scaled connectivity as a metric for pan-cancer compar-
isons as it corrects for network size, which the Jaccard distance is not guaranteed to.
The mean scaled connectivity is defined as the average connectivity, that is number of
partners in the network for each node, divided by the degree of the most connected
node in the network. Thus it is a value between 0 and 1, with 1 indicating a fully
connected network.
4.2.3 Resulting networks, evaluation, and comparisons
Mutation-expression networks were generated for 19 cancers
In this study, we considered the mutation and gene expression information from 19
cancers from TCGA. Using sets of mutated genes ranging from 2 to 690, with a median
of 223, shown in Table 4.1, DE testing was done on partners among the UPPI network.
Of the 19 mutation-expression networks, four corresponding to KICH, LAML, OV and
PRAD were empty, and others contained between 6 and 241 nodes and between 4
and 178 edges. In the pathway testing setting, gene sets with fewer than 5 genes were
removed, resulting in a total of 223 sets to interrogate. All networks are visualised in
Figure 4.4.
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Figure 4.4: Observed mutation-expression networks for each cancer. For each cancer
we visualised the direction mutation-expression network, where red edges
represent downregulation and blue upregulation. Trivial networks (KICH,
LAML, OV and PRAD) have no edges and are not visualised.
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Figure 4.5: Enrichment of generated networks. The heatmap displays comparisons of
the non-empty networks generated for each cancer against networks gen-
erated through randomly permuting the sample and gene labels. The top
heatmap is for the HIPPIE network and bottom is for UPPI. Cancers are
ordered in increasing overall mutation rate. Enrichment of genes among the
NCG 4.0 (An et al., 2014), CGC (Futreal et al., 2004) and DrugBank (Law et al.,
2014) databases, as well as the driver nodes identified through DriverNet
algorithm are displayed, using all nodes in the directed network, the tail
nodes and head nodes respectively. Cell colours correspond to empirical
p-values, blue closer to 1 and white closer to 0, with empirical p-values less
than 0.1 enumerated.
Known cancer genes are enriched in identified networks
Using various external databases as sets of known cancer genes, listed in Table 4.3, as
well as the set of ‘driver genes’ identified using the DriverNet algorithm on the same
dataset, we observed a significant enrichment of known cancer genes in a number of
the more highly mutated cancers, compared to permuted data. Figure 4.5 displays
the unadjusted empirical p-values generated by comparing across 1000 permuted data
networks, using the UPPI network. Results for both the HIPPIE network and UPPI
are given in Figure C.5. Cancers are ordered by overall nonsilent mutation load, and
both head and tail nodes are considered, as well as all nodes. Networks for which the
observed network is empty are shown as white cells. Significant enrichment (P<0.05)
of genes in the Network of Cancer Genes (NCG) 4.0 database among all nodes was
observed in BRCA, HNSC, LUAD, LUSC and UCEC, with these cancers also enriched
(P<0.05) in DriverNet driver nodes. This enrichment over permuted networks suggests
that the observed networks can lead towards biologically relevant signal. Very little en-
richment was observed among Cancer Gene Census (CGC) and DrugBank genes across
cancers, with a notable exception of head nodes significantly enriched for DrugBank
4.2 pacmen 78
Figure 4.6: Filtered observed melanoma network Red arrows indicate downregulation
in the head of the gene when samples are divided via mutation in the gene
at the tail of the arrow, and blue arrows indicate upregulation. Lone pairs of
nodes not in any database are removed for clarity, and blue labelled nodes
are those that appear in the DrugBank database. The genes MAPK1 and
JAK2 have 2 or more arrows pointed to them, indicating they are observed
to be DE through more than two mutated genes.
genes in the SKCM dataset among UPPI. Of these head nodes 22 of the 88 belong to
the DrugBank database (including ATM, CALM1, CFTR, DPP4, EGFR, FCGR3A, FGA,
ICAM1, IFNAR1, JAK2, MAPK1, MAPK3, MME, NID1, PIK3CB, PLAUR, PRKCB, RAC1,
RAF1, SERPINE1, SRC, and VEGFB). The network diagram for SKCM is shown in Fig-
ure 4.6. Indeed, a number of these genes are known to be related to melanoma, for
instance the genes MAPK1, MAPK3, PIK3CB, and RAF1 are in the KEGG pathway cor-
responding to melanoma. In addition, the genes PRKCB and RAC1 are also within the
KEGG MAPK Signaling Pathway, as expected given the number of drug targets within
this pathway identified in melanoma over the last decade (Krauthammer et al., 2012).
Considering furthermore the bipartite network generated by testing for differential
gene sets across mutated genes, shown in Figure C.6, the KEGG pathway correspond-
ing to melanoma is connected to by the genes NRG3 and SLC38A1. NRG3 is a ligand of
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Figure 4.7: Similarity matrices of mutated genes and cancers. Smaller values corres-
pond to more similar sets. Diagonal entries are removed. A: Concordance
of genes within cancers’ networks. The upper half of the heatmap displays
the Jaccard distance for the cancers in which these tail nodes appear. The
lower half of the heatmap displays the Jaccard distance corresponding to
the head nodes, i.e. the gene expression targets. Values range from 0 to 1.
B: Comparison of cancers via network statistics. The dendrograms rep-
resent hierarchical clustering using the number of nodes in the networks,
the mean scaled connectivity, and the amount of overlap of nodes in the
networks themselves. Cancers are coloured by their overall mutation load,
where blue represents the five lowest mutated cancers, purple the next five
mutated cancers and red the most mutated cancers.
ERBB4, previously shown to be related to melanoma (Cifola et al., 2013; Prickett et al.,
2009).
DE genes targeted by the same mutated gene tend to be more correlated
We next attempted to explore the relationship between DE genes that were found to
be so via the same mutated gene, i.e. through the same sample split. We looked spe-
cifically at the observed mutation-expression network for SKCM using UPPI, shown
in Figure 4.6. Upon identifying 40 pairs of shared DE targets, and comparing their
absolute Pearson correlations of gene expression against all 7,260 possible pairs by
repeatedly randomly selecting 40 pairs, we found the shared targets were more correl-
ated than expected by chance (empirical p-value < 1× 10−5). While the model does
not specifically test for correlation, we do observe that shared DE targets tend to be
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more correlated. The strongest association observed was between genes HSPA1A and
HSPA1B, which is not surprising as they share function.
Mutated genes tend to co-occur over cancer networks while gene expression targets do not
We observed that while the mutated genes are fairly co-occurrent over cancers, there
is little observed overlap in their gene expression targets. Figure 4.7A is a heatmap
displaying the Jaccard distance metric for sharing of mutated genes (top half of heat-
map) and for sharing of the gene expression targets (bottom half of heatmap). This is
displayed for genes that are observed in 2 or more cancer networks. This leads to the
possible suggestion that similar mutated genes may not lead to the same downstream
effects in different tissues in which these cancers originate.
Furthermore, we compared the cancers themselves by considering the co-occurrence
of the nodes within each of the cancer networks. Figure 4.7B is a hierarchical clustering
performed using three metrics, the number of nodes of the network, mean scaled con-
nectivity and overlap of nodes measured via Jaccard distance metric. Cancers with a
higher overall mutation load lead to larger networks, however the relationships among
highly mutated cancers do not persist when considering other metrics, suggesting
some other relationship between these cancers. For example BLCA and HNSC, and
SKCM and LIHC are clustered closely in terms of their scaled connectivity.
4.2.4 Interactive visualisation of networks
In order to facilitate straightforward examination of the networks under varying
threshold values, we developed an R Shiny interface, PAn Cancer Mutation Expres-
sion Networks (PACMEN), shown in Figure 4.8. This allows dynamic visualisation
of observed mutation expression networks under various scenarios, such as signific-
ance threshold, number of highly connected nodes to include, and number of mutated
genes to include. As datasets become more complex, use of interactive and analytic
tools come into their own for facilitating discovery. Our platform for interrogating the
observed networks named PACMEN is currently available via an online and interactive
R Shiny interface at the URL www.shiny.maths.usyd.edu.au/PACMEN_CBC.
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Figure 4.8: Screenshot of the PACMEN R Shiny application. Options include choice of PPI network (UPPI or HIPPIE), cancer dataset,
quantile threshold for mutated genes to be included in network, degree threshold for highly connected proteins to be included in
mutated gene test, significance threshold (FDR-controlled) for DE genes. Other options include highlighting nodes in databases
(Cancer Gene Census, DrugBank, and Network of Cancer Genes 4.0), removing pairs not in the selected database from display,
and finally ability to download the static subnetwork graph or to download the subnetwork table itself. PACMEN is available at
www.shiny.maths.usyd.edu.au/PACMEN_CBC.
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4.3 integrative test of mutation scores and coexpression hubs for
unmatched data
An active area of interest in cancer research is relating information about gene expres-
sion and coexpression patterns and somatic mutations in the context of prognostic
outcome. In the current section we detail an approach encompassing these facets. This
approach need not be applied to the same set of individuals, particularly useful to
make use of the entire dataset and not be required to potentially drastically filter pa-
tients with both mutation and expression data available. This approach does however
assume that both sets of individuals are representative of the population of cancer.
Previous work in breast cancer (Taylor et al., 2009) showed that proteins with many
interaction partners, so-called ‘hubs’, exhibited a low, high, or intermediate degree of
gene coexpression correlation with their directly binding protein interaction partners.
Moreover, the degree of coexpression correlation in these hub networks was signific-
antly disrupted in patients who died from the disease. The relevance of network-level
transcriptional disturbances to patient clinical outcome has also been supported by
work in human medulloblastoma showing that local protein interaction networks from
candidate driver genes were highly relevant to survival-related molecular subtypes
(Genovesi et al., 2013).
Hub-based PPI networks were recently analysed in relation to patient clinical out-
come in metastatic melanoma (Schramm et al., 2013a), identifying 32 hub proteins
with significant disturbances in the organisation of expression in relation to patient
survival. Following on from these observations we hypothesised that members of hub-
centric PPI networks in which gene coexpression correlation was disturbed in associ-
ation with patient survival were more likely to be mutated compared with equivalent
networks without such associations. Support for this idea was found by showing that
genes within the networks of interest were significantly (p-value<0.05) mutated above
a background rate (Schramm et al., 2013a).
In the present section we introduce a framework to identify and validate survival-
associated transcriptional disturbances in PPI hub subnetworks, and we show in four
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different cancers these survival-related network differences are significantly associated
with increased driver gene score (DGS) and/or changes in gene copy number variation
(CNV), implicating them in disease development and/or progression. Systematic prior-
itisation and literature analysis confirmed that the mutated members of these networks
are highly biologically relevant to the cancer in which they were identified of which
some are already clinically actionable therapeutic targets and/or prognostic biomark-
ers. This approach therefore provides a clear and rational basis on which to focus
the urgent and ongoing search for mutations responsible for cancer development: the
mutated members of disturbed PPI networks.
4.3.1 Scoring somatic mutations
Somatic mutations can be scored based on various characteristics of the mutations,
in order to prioritise genes or mutations that are of interest, either to understand the
cancer etiology or to develop treatment strategies. These are based on aspects such as
evolutionary conservation (Reva et al., 2011; Choi et al., 2012), and functional effect via
the corresponding amino acid effect, as well as binding properties of the corresponding
protein structure (Nishi et al., 2013). Furthermore, taking into account the network
topological effect has been found to be useful (Li et al., 2011). A detailed review for
predicting the functional impact of nonsynonymous mutations is available (Frousios
et al., 2013).
Combining mutation information over multiple patients or samples allows to pro-
duce a score associated with overall function as well as prevalence in the population of
tumours. For instance, Hodis et al. (2012) defines the functional mutation burden score
as a weighted average of mutations associated with each gene for a particular cancer
or cancer subtype. In the current section we obtain a DGS using the testing proced-
ure of MutSigCV (Lawrence et al., 2013), where a larger score value implies increased
evidence of a higher number of mutations acquired than expected by chance.
In a similar vein to somatic mutations, copy number variations are a change that
occur to DNA, leading to a different number of copies of genes in the genome. These
fall into the category of structural variations, where sections of the DNA sequence
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Figure 4.9: Schematic of integrative test for coexpression and mutation disturbance
with unmatched samples. Gene expression data were used in conjunction
with PPI networks to identify hub subnetworks that were significantly dis-
turbed in their gene coexpression pattern (Jayaswal et al., 2013). Next, the
multiple lists of hub subnetworks generated from each PPI network ana-
lysed were combined using a meta-analysis to identify a single list of hubs
related transcriptionally to patient clinical outcome. To test whether pre-
dicted functional mutation(s) might be an explanation for the network dif-
ferences observed, the interaction partners of these hubs were then tested
for overrepresentation of driver gene score (DGS) (Lawrence et al., 2013) and
copy number variation. These interaction partners were then evaluated via
literature review for their clinical actionability.
appear repeatedly, or not enough. Increase in copy number can lead to increased gene
expression contributing to various downstream effects contributing towards growth
and spread of cancer (Shlien and Malkin, 2009).
4.3.2 Differential network gene coexpression
In cancer, gene expression undergoes major changes for a potentially large proportion
of genes. Furthermore, regulatory mechanisms break down and can lead to changes
in coexpression of genes. Taylor et al. (2009) interrogated differential network gene
coexpression between poor and good prognosis groups in breast cancer and found
evidence for widespread disruption of key networks. In the current section, we use the
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statistic Ti proposed by Taylor et al. (2009) calculated over each ‘hub’ gene i with five
or more interactors in the PPI, specifically the mean of absolute differences in Pearson
correlation across all interactors j = 1, 2, 3, ...,n with the hub gene i,
Ti =
n∑
j=1
|rGPij − r
PP
ij |/(n− 1)
where rGPij is the Pearson correlation between genes i and j among the good prognosis
(GP) set of samples, and similarly rPPij for poor prognosis (PP) samples. This is im-
plemented in the Variability Analysis in Networks (VAN) R package (Jayaswal et al.,
2013), with significance obtained by using repeated permutation of sample prognosis
labels. Subnetworks belonging to these significant hub genes are termed as disturbed
subnetworks.
4.3.3 Data curation and testing
We coanalysed three high throughput data types: tumour gene expression data with as-
sociated clinical annotation, somatic mutation information (single nucleotide and copy
number variations), and PPI networks (Table 4.2), summarised in Figure 4.9. Transcrip-
tome data for cutaneous melanoma, lung squamous cell carcinoma, serous ovarian
cancer, and lung adenocarcinoma were obtained from TCGA. Additional independ-
ent cohorts were obtained from curatedOvarianData (Ganzfried et al., 2013; Tothill
et al., 2008) and the previously published work in metastatic melanoma (Jayawardana
et al., 2015; Mann et al., 2013). LUSC and LUAD were selected because they exhibit a
high overall mutation burden, similar to SKCM; OV was selected because it exhibits
a low overall mutation burden compared to SKCM (Alexandrov et al., 2013). Survival
thresholds were chosen on the basis of clinical relevance according to the literature
with consideration also given to sample size in terms of statistical power (Figure C.7).
Significant (p-value<0.05) disturbances in gene coexpression correlation between pa-
tient survival groups were identified using Variability Analysis in Networks (Jayaswal
et al., 2013), incorporating experimentally determined PPI information from multiple
sources, as described (Rolland et al., 2014; Schramm et al., 2013a). DGSs were calcu-
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lated via MutSigCV (Lawrence et al., 2013) using somatic mutation data from TCGA.
CNV data were also obtained from TCGA. Members of survival-associated hub subnet-
works were assessed for significant enrichment of mutations via DGS using Fisher’s
exact test (FET). Significant hubs are listed in Table 4.4 for each analysed dataset. Fi-
nally, we performed a systematic literature review of the most frequently mutated
interaction partners to determine the strength of their known associations with cancer.
An overview of this framework is in Figure 4.9.
4.3.4 Biological impact
Observed disturbed networks over multiple cancers identify clinically relevant genes
In each of the four cancer types, PPI networks were found to be disturbed in association
with poor outcome, and in each cancer type some interaction partners within those dis-
turbed networks were found to be significantly mutated. For melanoma (SKCM) 48 of
631 disturbed (p-value<0.05) PPI networks contained seven significantly (defined as
positive driver gene score DGS>0) mutated interaction partners (FET p-value<10−5).
In serous ovarian cancer (OV) 324 networks were disturbed (p-value<0.05) and TP53
(DGS>0) was the only significantly mutated interaction partner, affecting 34 networks
(FET p-value<10−5). In squamous carcinoma of the lung (LUSC) 424 networks were dis-
turbed (p-value<0.05) and six interaction partners were significantly (DGS>0) mutated
(CDKN2A, NFE2L2, PTEN, KEAP1, RB1, and TP53), affecting 42 networks (FET p-
value<0.001). In lung adenocarcinoma (LUAD) 465 networks were disturbed (p-value<0.05)
and 21 interaction partners were significantly (DGS>0) mutated, affecting 50 networks.
Of these 26 mutated genes identified (DGS>0), 15 have been previously causally asso-
ciated with cancer, and of the 11 novel genes three are existing drug targets and are
thus potentially clinically actionable.
The capacity of this approach to point to therapeutically relevant disease drivers is
evidenced by its identification, within transcriptionally perturbed hub subnetworks, of
mutated interaction partners that had previously been causally implicated in cancers
according to COSMIC (Futreal et al., 2004) and were already drug targets as reported
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Table 4.4: Summary of data analysed and results. For each cancer analysed, We list the
source of data analysed, cohort inclusions, sample sizes, significance value
for the relationship between hub subnetwork and driver gene score, and the
list of names (by hub) of each significant (p-value<0.05) hub subnetwork. An
extended table is available in the Appendix Table C.2.
Cancer Survival definition Samples (good:poor) p-value
Metastatic
melan-
oma
GSE59334
Good: >4yr Poor: <1yr 25:22 <0.05
Hub
Names: DHFR DVL2 HIF1A HUWE1 MAP2K1 MRAS NDN NFKBIA PARP1PSMC3 S100A8 SAT1 SERPINB9 TOP1 USP7
TCGA:
SKCM Good: >3yr Poor: <2yr 11:12 <1E-6
Hub
Names: A2M AKT1 ATR AURKA BACH1 BAK1 CCT5 CDK4 COPS5 CREB1DVL2 E2F1 E4F1 EIF2AK2 GPS2 GTF2H1 HRAS HSPB1 IMMT MAPK9
MDM2 MNAT1 MTA1 NDN NEDD4 NEDD8 NPM1 ORC4L PLK1
PML PRMT1 PRSS23 PSMD11 PSME3 RAP1GAP RPA1 SERPINB9
SMARCA4 STK11 TAF6 TFDP1 TK1 TOPORS UBE3A UTP14A WRN
YY1 ZNF24
TCGA:
LUSC Good: >4yr Poor: <3yr 14:12 <0.001
Hub
Names: AHR ARIH2 BCL2L1 CASP9 CCNA1 CDK1 CDKN1A CHEK1 COX17CUX1 DAXX E2F4 E4F1 HUWE1 ING1 ING4 KEAP1 MAGI3 MBIP
MDM4 MTA1 MYC NFE2L2 NR3C1 PARP1 PELP1 PIN1 PLK1 PMF1
PRKDC PTK2 RBX1 S100A4 SAT1 TAF6 TOP1 UTP14A WRN YWHAH
YWHAZ YY1 ZNF24
TCGA:
OV Good: >3yr Poor: <1yr 86:14 <1E-8
Hub
Names: AIMP2 ATF3 BARD1 CCL18 CCT5 COX17 EGR1 GPS2 HDAC2 HNF4AHNRNPUL1 ING5 MAD2L1BP MDM2 MDM4 MED1 MED17 MNAT1
NDN NPM1 NR4A1 PIN1 PNP PRKRA PTTG1 SAT1 SETD7 SUMO1
TADA3 TAF9 TBP UBE2A UBE2I WRN
TCGA:
LUAD Good: >2yr Poor: <1.5yr 219:48 <0.002
Hub
Names: ABL1 ADRB1 AR ATF3 BCR BRF1 CD28 CEACAM1 CSF1R CSF3RCUL3 DCN EGR1 EIF2AK2 EPHA2 FER FRS3 GAB1 GRB10 HIPK2
HNRNPC IL16 ING4 ITK MORF4L1 NEDD8 NPM1 PIK3CG PIN1
PLK1 PRKCB PRKD1 PRMT2 RAP1GAP RAPGEF1 RBBP4 RHEB
RUVBL1 S100B SELL SH2D1A SMARCE1 STAT3 TAF6 TBP TOP2B
UBC UBTF USP4 YBX1
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in DrugBank (Law et al., 2014) (Tables C.3,C.4,C.5,C.6). BRAF and TP53, for example,
were identified in both melanoma cohorts. These mutations are well established as
disease drivers in approximately 50% and 19% of cutaneous melanomas, respectively
(Akbani et al., 2015; Hodis et al., 2012). Notably, BRAF mutation has been reported
(Mann et al., 2013) in association with patient survival: the basis on which our networks
were identified to begin with. The LUAD analysis identified current therapeutic target
EGFR and current investigational target BRAF (Collisson et al., 2014). Both genes are
frequently mutated in the disease (14-33 and 10%, respectively) and EGFR mutation
is associated with better survival (Ding et al., 2008; Collisson et al., 2014). The tumour
suppressor RB1 was distinguished in both the LUAD and LUSC experiments (4-8 and
7%, respectively) (Hammerman et al., 2012; Collisson et al., 2014). While RB1 is not
currently a direct target for therapies (Swanton and Govindan, 2016) it has been under
investigation as a marker for sensitivity to cytotoxic chemotherapies (Knudsen and
Wang, 2010). The P53 regulator, ATM, was also identified in the LUAD data.
Biologically important gene mutations and drugs for potential repurposing
Our approach also identified several interaction partner mutations that were already
causally associated with cancer but for which there were no prior reports of exist-
ing or potential targeting compounds in DrugBank. We propose the genes in this cat-
egory warrant priority investigation for their potential as therapeutic targets (Tables
C.3,C.4,C.5,C.6). They include PTEN and CDKN2A, observed in both melanoma data-
sets, as well as NF1 observed in TCGA SKCM data only. Indeed, both PTEN and
CDKN2A are common mutations in melanoma (12% and 38%, respectively) while in-
terest in NF1 mutations has surged after recent evidence of its notable prevalence
(approximately 25%) in tumours without highly recurrent (and presently targetable)
BRAF or NRAS mutations (Hodis et al., 2012). In LUAD, our analysis pointed to tu-
mour suppressors CDKN2A, ARID1A, SMARCA4, and STK11, and oncogenes KRAS
and CTNNB1. Altogether, these mutations occur in more than 65% of tumours and as
such are already under investigation for their clinical prospects as direct targets (Col-
lisson et al., 2014). Similarly in LUSC, our approach highlighted CDKN2A, NFE2L2,
4.3 integrative test of mutation scores and coexpression hubs for unmatched data 89
and PTEN which were recently identified as disease drivers in 15 and 8% of tumours,
respectively (Hammerman et al., 2012). Notably, NFE2L2 has been reported in relation
to poor prognosis (Shibata et al., 2008) and investigations are ongoing.
A corollary of the above is that the mutated network members not previously re-
ported as causal associates of cancer but for which targeting compounds already exist,
would merit further basic research into their potential biological relevance to the dis-
ease including the prospect of drug repurposing (Tables C.3,C.4,C.5,C.6). Genes from
two cancers examined fall into this category: GRB2, KEAP1, and CD4 in LUAD; and
B2M in SKCM. This highlights the potential of our integrated approach to identify
future directions for cancer research.
New research directions are identified by the approach
Our approach identified a fourth category of genes of interest from the survival-
associated PPI networks: mutated interaction partners neither previously causally as-
sociated with cancer nor already existing drug targets (Tables C.3,C.4,C.5,C.6). The
SKCM analysis identified one such candidate in NDUFB9, involved in cellular respir-
ation. Prior reports suggest a role for this protein in suppression of breast cancer cell
proliferation, migration and invasion (Li et al., 2015b). Additionally, the Human Protein
Atlas (Uhlen et al., 2015) reports differential staining (undetected, weak, or moderate)
of the protein in ten melanoma samples, as well as in other cancers, so it may be that
NDUFB9 is a potentially important target or biomarker. As such, further investigation
appears warranted.
We developed an approach that leveraged multiple types of high throughput data
from four different cancers, to identify and prioritise network-based gene alterations
with the most promising potential for clinical actionability. We showed that members
of survival-related PPI hub-subnetworks were more likely to be enriched for functional
mutations than expected by chance. The biological relevance of this observation is in
the suggestion of mechanisms by which selection for tumour-promoting processes has
occurred. This prediction is directly relevant to target selection for drug and clinical
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trial development in cancer, as our consequent literature review of mutated genes in
disturbed networks confirms.
4.4 discussion
Exploring the information rich datasets pertaining to gene expression and somatic
mutation is useful in uncovering regions of cancer networks that are biologically in-
teresting. Furthermore, examining the relationships between somatic mutations and
gene expression changes can uncover complex regulatory elements at play. Integrated
data analysis approaches can aid this process by bringing to light informative areas
of the networks in silico and in a high throughput manner. This chapter has focussed
on developing frameworks to help unravel the underlying mechanism behind cancer
presentation and spread, an inherently challenging task due to the complex nature of
the relationships truly present.
In this chapter we introduced a framework for building mutation-expression net-
works, highlighting potential associations between nonsilent mutations and gene ex-
pression. We have done so within a pan-cancer study utilising external information
from PPI networks and pathway sources such as KEGG. We observed that networks
generated contain known cancer related genes. We have also examined the topological
structure of these networks and the relationships among recurrently mutated genes
across cancers. Our platform for interrogating the observed networks, PACMEN, is
available via an online and interactive R Shiny interface at the URL
www.shiny.maths.usyd.edu.au/PACMEN_CBC.
We have evaluated our results in a similar manner to others in this area (Bashashati
et al., 2012; Jia and Zhao, 2014) by considering the enrichment of known cancer genes
from various sources. Wet lab validation is outside the scope of this thesis. Using
databases is clearly useful but we must be aware of selection and research bias. Some
genes are well studied and are thus well represented in the databases, and different
network relationships are present in different PPI networks (Schramm et al., 2013b).
Since cancer is a disease with a large component related to mutations then it is likely
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there are positive biases in the databases, however this is a common challenge faced in
evaluation of work within the field of computational biology.
Using external data and prior biological knowledge can be concerning due to the
uncertainty of reliability or relevance of the information extracted. This point can be
raised in light of the present study given that external information sources such as
PPI networks and pathways were used. We constructed a new network by taking the
union of 5 PPI networks in efforts to mitigate bias towards any one database or net-
work. Given the differences of these networks as previously described (Schramm et al.,
2013b), considering the union network is preferable over the intersection network. Had
we made use of the intersection network, we would have been restricted down to only
33 edges among 701 nodes. As network databases continually improve, the effects of
biases towards any particular database will clearly diminish. We also used another
source of information for PPI networks called HIPPIE (Schaefer et al., 2014). Certainly
it is possible to attempt to circumvent the use of external information such as PPI
networks altogether by making use of any biologically relevant network for this ap-
proach, including networks that are data-driven themselves such as that generated
from Weighted Gene Correlation Network Analysis (WGCNA) (Fuller et al., 2007). Fur-
thermore, using different networks such as a gene regulatory network (GRN) can un-
veil other aspects of the relationships between mutations and gene expression changes,
potentially leading identifying causal relationships between mutated genes and their
targets. The mutation-expression subnetworks highlight hotspots or functional regions
in the global network of molecular interactions that are related to the properties of
cancer or are oncogenic. Further work includes considering the mutation expression
subnetwork over a GRN generated either through a priori information or estimated
from the available data.
The reliance on choosing reasonable parameters in any framework is an important
issue to consider. Changing parameters can lead to different numbers of nodes drawn
in the network, as well as the number of edges drawn. For instance, increasing the sig-
nificance threshold will result in more edges being drawn in the mutation-expression
network, although the proportion of true signal may diminish; and increasing the num-
ber of mutated genes to test for DE can increase both the number of nodes and edges in
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the network, and again true signal can be lost amongst the noise. Furthermore, using
weighting schemes on various edge and node statistics such as -log(p-value) may be
useful. This can remove the somewhat arbitrary choices of parameters, but can limit
interpretability in visualisation as well as dramatically increase computational load by
generating weights for all possible connections. One way of attempting to bypass the
issue of parameter selection and still choose some kind of optimal network is to in-
troduce a condition that should be satisfied. For example, selecting networks that are
scale-free in their topology, implemented previously (Fuller et al., 2007) and explained
in more detail (Barabási et al., 2011), may be useful.
In the chapter, our approach has been to consider nonsilent mutations. The premise
behind this is that there should be a change in the amino acid sequence that could lead
to a plausible difference in gene expression. It is entirely possible that some informa-
tion is lost by only taking these into account, such as the effect of intergenic mutations,
as they can be situated in genomic regions important to aspects of gene regulation,
such as promoter regions, but are classified as silent and thus removed from the ana-
lysis. Technical differences like sequencing coverage between and within samples can
lead to issues to do with detecting mutations.
The methods we described can also be expanded to other biological platforms. While
clearly somatic mutations play a role in cancer development and progression, other bio-
logical mechanisms may be at play. For example, copy-number alterations, germline
mutations as well as regulatory factors like microRNA expression or epigenetic factors
such as DNA methylation could potentially be affecting the true biological cancer net-
work. The method we describe is implemented presently by considering nonsilent so-
matic mutations, however it is easily expandable to other measures of biological phe-
nomena. In essence, what can be used in this context is any measure in which two
or more sets of measurements are made on similar sets of data for the same sample
cohorts. The binary matrix used to split the samples need not be binary; in fact it can
be replaced with a continuous matrix and the hypothesis testing framework would
simply change from a moderated t-test to a moderated linear regression.
A further extension to the work presented in this chapter is to address the heterogen-
eity and multiclonality of cancer. In reality tumour tissues are hugely heterogeneous,
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and what we observe is in essence an aggregate of individual tumour cell networks
which will need deconvolving. Emerging technologies such as single cell RNA-Seq
will aid in this process, especially technology that obtains DNA and RNA of the same
cells (Dey et al., 2015), allowing retrieval of matched DNA and RNA information for
not only the same patients, but the very same cells. The emerging technology brings
about the promise of a deeper understanding of tumour cell networks, which will in-
variably require development of sophisticated statistical methods to obtain meaningful
patterns.
5
C O N C L U S I O N
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This thesis has demonstrated the immense potential for utilising data stemming
from multiple high throughput sequencing technologies to develop novel statistical
approaches. The combination of each data type and the context in which it is used
has unique characteristics and associated statistical challenges that require addressing.
The four main contributions of this thesis have been the development of a statistical
approach to characterise allelic imbalance from RNA-Seq data, the development of a
mixture modelling framework for standardisation and estimating single cell-specific co-
activation networks in single cell RNA-Seq data, as well as development of two frame-
works for relating cancer gene expression and somatic mutation data in the case where
samples are matched and not necessarily matched, utilising RNA-Seq and Whole
Exome Seq data. These results have been published in Ghazanfar and Yang (2016),
Ghazanfar et al. (2017), and Ghazanfar et al. (2016), and presented at YSC2015, APBC
2016, INCOB 2016, ABACBS 2016 and ASC 2016. These novel works highlight the im-
portance of tailoring approaches to the specific question at hand as well as the data
and external information available. Some emerging themes have come to light upon
completion of this work, which will only become more important as modern statist-
ical bioinformatics research progresses. Additionally, as technology advances continue
in the field of high throughput sequencing (Goodwin et al., 2016), for instance with
the rise of long-read sequencing technologies like that of Pacific Biosciences (Eid et al.,
2009) and Oxford Nanopore (Clarke et al., 2009), statistical techniques to interrogate
data arising from these new technologies continue to be developed in the context of
the biological questions asked. Specifically these technologies promise lower technical
error associated with existing short-read sequencing such as read mapping errors to
the genome or transcriptome, and have the potential to lead to higher resolution in
identifying large structural changes in the DNA and RNA sequence such as genomic
rearrangements in cancers. Furthermore long-read sequencing will be useful in the
study of allele-specific genetic effects such as allele specific gene expression as was
studied within this thesis in Chapter 2, potentially leading to data in which specific
relationships of variants can be characterised accurately.
High throughput sequencing data allows us to ‘zoom’ in to the genomic data, where
the smallest unit of resolution is a single nucleotide in the sequence. For instance, we
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can interrogate individual point mutations instead of mutated genes, to expression of
individual exons instead of genes, and to individual SNPs instead of genes. This in-
crease in potential resolution however comes with the associated cost via increase in
dimensionality, in computational cost, and increased difficulty in interpretability. Thus
it is important to identify what is most appropriate for the biological study, and in
particular be able to identify when ‘zooming out’ is a better approach for the problem
at hand. In Chapter 2 we performed our testing on SNPs and later reported allelically
imbalanced genes as this was more interpretable and relatable to the role these play to
the traits these livestock harbour. Similarly in Chapter 4 we considered mutated genes
rather than single mutations, as we would be trading off between specificity of particu-
lar mutations and tremendously increased dimensionality and sparsity of the data. As
discussed in Chapter 3, single cell RNA-Seq has led to increased resolution in terms
of the biological samples analysed, from tissues to single cells. As experimental tech-
niques continue to develop, for example to enable measurement of multiple platforms
on the same cell such as DNA and RNA (Dey et al., 2015) or RNA and methylation
(Angermueller et al., 2016), as well as spatially map cells (Huang et al., 2015; Achim
et al., 2015), statistical techniques are required to understand these data in the context
of the biological questions at hand.
Through the work presented in this thesis, we can also appreciate that networks are
a powerful tool for interacting with the data. Many pieces of information curated can
be summarised in a network, for instance PPI information, but generating networks
can allow for efficient exploration and can enable insight of the high dimensional data
on hand. In Chapter 3 we defined cell-specific coactivation networks, which allowed
us to identify characteristics of the cells from which they were derived in terms of the
network topology of its associated network. In a similar vein in Chapter 4 we defined
and estimated mutation expression networks for each cancer, distinct subnetworks of
the second degree PPI network but with added direction. These networks allowed us
to identify highly connected hub genes, as well as compare topological features across
multiple cancers.
The research presented in this thesis is at the interface of statistics and bioinformat-
ics. Biology is inherently complex and great technological advances have been made
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in capturing this complexity. Thus, the development of statistical techniques to analyse
complex and high dimensional data is driven by availability of such biological data.
Interactive tools such as R Shiny are paving the way in allowing a simple interface
between the statistician or bioinformatician and the high-dimensional and complex
data. In Chapter 4 we developed the R Shiny application PACMEN to embed interact-
ive interrogation of the estimated mutation-expression networks our framework pro-
duced for each cancer, with a simple interface for varying thresholds and visualising
the resulting networks.
In summary, the work presented in this thesis represents an investigation of the
many facets high throughput sequencing can offer in diverse biological contexts. We
have developed approaches to address statistical issues in varying contexts and the
immediate consequences from this work has been to increase understanding of specific
biological systems as well as building statistical tools and frameworks that can be
applied in multiple settings.
A
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RNA Extraction and RNA-Seq Library Preparation
The RNA extraction and RNA-Seq library preparation described in this section was performed
by Janna L. Morrison, Lisa M. Nicholas, and Isabella C. McMillen, and is provided in this
Appendix for completeness.
Procedures involving animals were carried out with approval from the University
of Adelaide Animal Ethics Committee. Pregnant ewes (n=18) were maintained on a
diet that provided 100% of their maintenance energy requirements (Great Britain. Min-
istry of Agriculture et al., 1975) and the ewes were individually housed from 110 days
post conception (dpc; term: 150 dpc) in pens for two weeks before sampling. These
animals have a common sire, although the dams were unrelated. The pregnant ewes
were humanely euthanased and fetuses removed and weighed at 132± 1 dpc. Perirenal
adipose tissue (PRAT) was collected from 18 fetuses (2 male and 16 female) and frozen
for analysis.
RNA was extracted from 1 g of each PRAT sample (Byrne et al., 2010) and RNA
quantity and integrity assessed using the Bioanalyzer 2100 (RIN scores > 9; Agilent,
Santa Clara, USA). RNA (5 µg) from each sample was used for library preparation
(TruSeq RNA Sample Preparation Kit v2 (Illumina, San Diego, USA) and sequencing
(paired end, 100 bp) was performed using a standard protocol for the HiSeq 2000 plat-
form (Illumina, San Diego, USA). The 18 sample libraries were assigned randomly to
three lanes for 6-fold multiplex sequencing in each lane. After removal of sequencing
adaptors, reads were subjected to recommended quality control assessments and filter-
ing. The quality of raw sequence reads was assessed using FastQC (Andrews, 2012).
Data is available online on GEO with accession number GSE79143.
Read Mapping
Reads were mapped to the ovine reference genome Oarv3.1
(http://www.livestockgenomics.csiro.au/sheep/) (Jiang et al., 2014) using STAR RNA-
Seq aligner (Dobin et al., 2013). Parameters in the read-mapping software were adjusted
to allow for mismatches representing rates of allelic variation known to be present
in the sheep population. Specifically, we set the maximum mismatch threshold to 10
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nucleotides, and only considered reads aligning to unique positions. Overall successful
read mapping rates ranged between 66.7% and 72.4%, with a median of 69.2% (Table
A.1).
SNP Discovery
SNP variants were identified from the mapped RNA-Seq reads using the UnifiedGen-
otyper tool in the Genome Analysis Toolkit (GATK) (DePristo et al., 2011). All default
parameters were used, with the exception of the minimum phred-scale confidence
threshold at which variants should be emitted (“stand_emit_conf”), which was set
at the value of 10, lower than the default value of 30. The output was a variant call
format (VCF) file containing the genomic coordinates, reference and alternate allele
nucleotides, and for each sample, read depths for both alleles, and inferred genotype.
The reference allele is the nucleotide agreeing with the Oarv3.1 reference genome.
SNP Filtering
We removed SNPs that were present in known repeat regions, as described by the
UCSC Simple Repeats track (Karolchik et al., 2004), and those that were not within an
ENSEMBL gene region (Cunningham et al., 2014).
We used SNP filtering steps to enrich for SNPs that are informative of AI status.
The aim was to filter for SNPs with sufficient read depth (indicative of minimal gene
expression). SNPs were retained if at least five of the 18 samples had 10 or more reads
for both the reference and alternate alleles (Stevenson et al., 2013).
Identification of SNPs Potentially Impacting Encoded Protein Function
The ENSEMBL VEP tool (McLaren et al., 2010) was used to identify potential impacts
of the identified SNP on the encoded proteins. This tool provided information pertain-
ing to amino acid changes (both conservative and nonconservative), changes in stop
positions and frameshifts as well as the position of SNP relative to transcripts.
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Identification of Functional Enrichment: Gene Ontology Analysis
In order to investigate the biological interpretability of our case study results, we used
a Wilcoxon rank sum test implemented using the goseq R package (Young et al., 2010b)
on 4,168 GO terms containing between 10 and 500 genes. Use of the Wilcoxon rank
sum test was ideal for this data since it does not require a p-value cut-off, and only a
ranking is necessary. The background gene set list was determined as the set of 5,810
genes corresponding to the filtered 24,355 SNPs tested for AI.
Software
As well as the aforementioned software, we used R for most of the analysis (R Core
Team, 2015). We also used the R package VariantAnnotation (Obenchain et al., 2014)
during the analysis.
Figures and Tables
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Figure A.1: Boxplot of mapped expression read counts over filtered SNPs for each of
the 18 biological samples. The y-axis is the log10 transformed expression
values.
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Figure A.2: Not downsampling leads to less biologically informative results. (a) The
first gamma plot shows that when using the original analysis framework
many highly significant SNPs are also very highly expressed, suggesting a
bias towards high expression. (b) The second gamma plot is generated for
one round of downsampling. (c) The third gamma plot shows the median
test statistics over twenty repetitions of downsampling, displaying stabil-
ity associated with the downsampling method as it is very similar to the
second gamma plot.
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Figure A.3: Heatmap of variant class for top 500 SNPs. For the 500 top ranked SNPs
for AI, the heatmap displays the class of the variant using the Ensembl
VEP tool. Variant classes with a green label (missense variant, splice ac-
ceptor variant, splice donor variant, and stop gained variant) are signific-
antly overrepresented in their ranking across all SNPs (Wilcoxon Rank Sum
Test P<0.01), indicating there are more of these types of SNPs more highly
ranked than expected by chance.
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Table A.1: Number of read pairs collected and mapped to the reference genome per
sample. Reads were only deemed successfully mapped if both paired reads
were uniquely mapped to the reference genome.
Sample ID Number of input reads Uniquely mapped reads number Percentage
PS910CR 40079468 29021746 72.41%
RS902PCV 26841667 18370208 68.44%
RS903CV 36543894 25933048 70.96%
RS905PCR 39210314 26833435 68.43%
RS917CV 46251180 32077318 69.35%
RS918CV 36176568 25006646 69.12%
RS919CR 39566696 27812920 70.29%
RS920PCV 40414417 26966797 66.73%
RS926CR 33087112 23017579 69.57%
RS929PCV 36158902 24378104 67.42%
RS930CV 40264154 28097684 69.78%
RS933PCR 32383590 22687453 70.06%
RS937PCR 45370183 30714067 67.70%
RS940PCV 41683149 28165815 67.57%
RS943CR 31968946 21909286 68.53%
RS947PCR 33803703 23602327 69.82%
RS953CV 39609081 28541931 72.06%
RS969PCV 41371752 28268296 68.33%
Table A.2: Table showing the number of SNPs in each of the different functional SNP
categories. The categories were provided by the Variant Effect Predictor an-
notation tool (VEP).
Category Number of SNPs
synonymous variant 13881
missense variant 4831
3 prime UTR variant 3470
downstream gene variant 423
5 prime UTR variant 314
upstream gene variant 189
intron variant 70
start lost 4
stop gained 18
stop lost 6
stop retained variant 7
splice acceptor variant 5
splice donor variant 3
other 1134
Total 24,355
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Table A.3: List of the top 30 ranked genes for significant AI, using the entire set of read counts. Columns correspond to Gene name, Location
of the most informative SNP, the Reference and Alternate Alleles for the SNP, which allele has higher expression, the number
of SNPs for that gene, the number of significant (P < 0.05) SNPs for that gene, the maximum χ2 statistic, the corresponding
minimum p-value, and the ranking.
Ranking Gene SNP Ref Alt HigherExpression numSnps numSigSnps maxChi minP
1 FTH1 chr3:31523952 C T Reference 9 7 60065.15906 0
2 VIM chr13:30748009 G T Reference 8 5 52788.2626 0
3 RPS3A chr3:192372078 T C Reference 2 2 29914.01274 0
4 CYCS chr4:70703303 A G Reference 1 1 18305.2073 0
5 PLIN4 chr5:17196981 G C Reference 10 8 15739.6925 0
6 IDH1 chr2:209240363 A T Reference 20 18 10121.25005 0
7 CLEC3B chr19:54064225 C T Reference 1 1 9110.731083 0
8 DCN chr3:127427540 C T Reference 9 9 8347.37813 0
9 TALDO1 chr21:49363664 T G Alternate 3 2 7553.062348 0
10 ITGA7 chr3:163492254 C G Alternate 9 8 7357.849707 0
11 ELN chr24:33210385 G C Reference 4 4 6895.978386 0
12 HSP70 chr20:26649584 C T Reference 5 2 6750.956116 0
13 RPL13A chr14:54973969 T C Reference 9 4 6479.401419 0
14 RPS23 chr3:43017676 T C Reference 3 3 6264.802229 0
15 COL4A2 chr10:84473565 G A Reference 17 11 5515.681429 0
16 SRRM2 chr24:2267059 A T Reference 14 12 4490.082028 0
17 RPS27A chr3:68706092 G C Reference 1 1 4372.506904 0
18 AHNAK chr21:40269856 T C Reference 12 5 4260.283298 0
19 COL3A1 chr2:119229532 T A Reference 13 11 4237.310688 0
20 DDX3X chrX:38493436 A T Alternate 6 6 4017.950568 0
21 HSPG2 chr2:243838658 G A Reference 61 37 3965.962861 0
22 OXCT1 chr16:32778194 T A Reference 7 6 3884.248582 0
23 TFPI2 chr4:11089206 C T Alternate 1 1 3827.788089 0
24 RTN3 chr21:41355521 C G Reference 19 14 3798.270867 0
25 ACTN4 chr14:47649628 C A Reference 20 18 3730.688192 0
26 NDUFV1 chr21:44748012 A G Reference 9 9 3721.105916 0
27 TMBIM6 chr3:136358483 A G Reference 12 12 3547.213976 0
28 GOT2 chr14:25869075 T G Reference 12 11 3051.98254 0
29 URM1 chr3:7828696 C T Reference 1 1 3010.749827 0
30 ODC1 chr3:19479349 A G Reference 3 3 2866.188328 0
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Table A.4: Top 20 ranked Gene Ontology Analysis terms for the initial ASE analysis, using all data. Columns correspond to term rank,
GO symbol, name of the term, the ontology (biological process (BP), molecular function (MF), or cellular component (CC)),
FDR-adjusted p-value, number of genes within the ontology term and number of genes outside of the term.
Ranking GO term Name Ontology FDR-adjusted p-value Number of Genes
in GO term
Number of Genes
not in GO term
1 GO:0019752 carboxylic acid metabolic process BP 7.70 ×10−17 390 5,405
2 GO:0055114 oxidation-reduction process BP 2.40×10−16 427 5,368
3 GO:0006082 organic acid metabolic process BP 2.40×10−15 430 5,365
4 GO:0043436 oxoacid metabolic process BP 2.40×10−15 430 5,365
5 GO:0005198 structural molecule activity MF 1.60×10−11 203 5,592
6 GO:0005615 extracellular space CC 5.60×10−11 297 5,498
7 GO:0044429 mitochondrial part CC 5.60×10−11 431 5,364
8 GO:0016491 oxidoreductase activity MF 1.70×10−10 273 5,522
9 GO:0048037 cofactor binding MF 1.60×10−8 133 5,662
10 GO:0032787 monocarboxylic acid metabolic process BP 2.70×10−8 218 5,577
11 GO:0005740 mitochondrial envelope CC 3.60×10−8 315 5,480
12 GO:0016054 organic acid catabolic process BP 4.20×10−8 103 5,692
13 GO:0046395 carboxylic acid catabolic process BP 4.20×10−8 103 5,692
14 GO:0050662 coenzyme binding MF 4.20×10−8 102 5,693
15 GO:0045047 protein targeting to ER BP 1.00×10−7 44 5,751
16 GO:0044282 small molecule catabolic process BP 1.10×10−7 151 5,644
17 GO:0006613 cotranslational protein targeting to membrane BP 1.50×10−7 40 5,755
18 GO:0044391 ribosomal subunit CC 1.80×10−7 56 5,739
19 GO:0006520 cellular amino acid metabolic process BP 2.20×10−7 173 5,622
20 GO:0072599 establishment of protein localization to endoplasmic reticulum BP 2.20×10−7 46 5,749
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Curating an olfactory gene list
In order to further interrogate the data for biological relevance, we curated a set of
genes of interest using Gene Ontology (GO) using the R packages GO.db v3.2.2 and
org.Mm.eg.db v3.2.3. GO terms were queried using the search term ‘olfa’, resulting in
a set of 33 terms related to olfactory processes such as ‘olfactory receptor activity’, and
a set of 1,129 genes that belong to these GO terms.
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Figure B.1: Violin plots of log2CPM values stratified by classification of 1 (lowly ex-
pressed), 2 (highly expressed) and NA (not enough data to classify) before
(left of dashed line) and after (right of dashed line) employing contextual-
ization of genes, resulting in better separation of log2CPM values between
classes 1 and 2, and removal of missing values from the method.
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Figure B.2: Scatterplots of total read depth versus number of non-zero log2CPM val-
ues (top left) and (middle left) number of active genes using all genes. Box-
plots (top right, middle right, respectively) are of the number of non-zero
log2CPM values and number of active genes using all genes respectively,
split by dataset. The last boxplot (bottom left) is of total read depth of
cells from various datasets. Unsurprisingly, we observe some relationship
between total read depth and number of non-zero genes (top left), which
is slightly diminished when comparing total read depth to the number of
active genes (middle left) for datasets with lower total read depth.
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Figure B.3: Scatterplot of number of olfactory genes with non-zero values against
number of olfactory genes classified as active (highly expressed). The
grey solid line is the diagonal line and other dotted lines are fitted lines for
each dataset.
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Figure B.4: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
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Figure B.5: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
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Figure B.6: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
additional information for chapter 3 114
l
l l
ll l
lll
l
l
ll
lAtf5
Axin1 Bcl11b
Dicer1Dlx5
Fezf1
Lhx2Olfr570Olfr610
Pou2f1
Robo2
Ttc8Ubr3
Uncx
Centralization: 0.85
SRR2961055
Unsure
l
l
l
l
l
ll
l
l
l
l
l
l
l
Agtpbp1
Atf5
Dicer1
Fezf1
Lhx2
Olfr987Olfr988
Reep1
Robo2
Rtp1
Rtp2
Ttc8
Ubr3
Uncx
Centralization: 0.85
SRR2961090
Mature
ll
l
l
l
l
ll
l
l l
l
l
l
Agtpbp1
Atf5
Dicer1
Dlx5
Fezf1
Lhx2
Olfr518Olfr570
Robo2
Rtp1
Rtp2
Ski
Ttc8
Uncx
Centralization: 0.85
SRR2961106
Unsure
l
l
l
ll
l
ll
l
l l
ll
l
Atf5
Csf1r
Dicer1
Fezf1Htt
Lhx2
Olfr372Olfr37
Reep1
Robo2
Rpgrip1l
Rtp1
Rtp2
Ubr3
Centralization: 0.85
SRR2911239
Unsure
l
l
l ll
l l
ll l
l
l
l l
l
Agtpbp1
Atf5
Bcl11b Dicer1
Eomes
Fezf1
Lhx2
Olfr1281
Olfr777 Reep1
Rtp1
Rtp2
Ttc8
Ubr3
Uncx
Centralization: 0.86
SRR2961084
Mature
l ll
l
ll
l
l l
l
l
l
l
l
l
Agtpbp1
Atf5
Dlx5
Lhx2
Olfr1054Olfr1055
Rac1
Reep1
Robo2
Rtp1
Rtp2
Ski
Ttc8
Ubr3
Uncx
Centralization: 0.86
SRR2961087
Mature l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
Agtpbp1
Atf5
Chd7
Dicer1
Lhx2
Olfr619Olfr620
Pcnt
Pou2f1
Robo2
Rpgrip1l Rtp1
Sema7a
Ttc8
Ubr3
Uncx
Centralization: 0.86
SRR2911124
Mature
ll
l
l
l
ll
l l
Atf5
Axin1
Bcl11b
Olfr1271
Rpgrip1l
Rtp1Rtp2
Shank1 Ubr3
Centralization: 0.86
SRR2911157
Immature
ll
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
Agtpbp1
Atf5
Bbs1
Bcl11b
Chd7
Dicer1
Dlx5
Ext1
Fezf1
Htt
Id2
Lhx2
Olfr1289Olfr449
Rac1
Robo2
Sema7a
Slit1
Centralization: 0.86
SRR2911235
Unsure
l
l
l
ll
l
ll
l
l
l l
l
l
l
lAgtpbp1
Atf5
Bcl11b
Chd7
Htt
Lhx2
Olfr330Olfr331
Pou2f1
Rac1
Robo2
Rtp1
Rtp2
Sema3a
Ubr3
Uncx
Centralization: 0.87
SRR2961052
Immature
l
l l
l
lll
ll
l
l
l
l
ll
l
l
Agtpbp1
Atf5 Bbs1
Chd7
Htt
Id2Lhx2
Olfr166
Olfr190
Rac1
Reep1
Rpgrip1l
Rtp1
SkiTtc8
Ubr3
Uncx
Centralization: 0.88
SRR2911282
Unsure l
ll
l
l
l
l
l
ll
ll
l l
l
l
l Agtpbp1
Atf5
Bcl11b
Dicer1
Ext1
Fezf1
Lhx2
Olfr231Olfr876
Robo1Robo2
Rpgrip1l
Rtp1
Sema3a
Slit2
Srf
Ttc8
Uncx
Centralization: 0.88
SRR2961048
Unsure
l
l
l
l
ll
ll
l
l
ll
l
l
l
l
l
l
Agtpbp1
Atf5
Bbs1
Bcl11b
Dicer1Lhx2
Olfr285Olfr531
Reep1
Robo1
Robo2
Rpgrip1l
Rtp1
Rtp2
Ski
Slit1
Ttc8
Ubr3
Centralization: 0.88
SRR2961068
Mature ll
ll
ll
l l
l l
l
l l
l
l
l
l
l
Agtpbp1
Atf5
Bcl11bCsf1r
Dicer1
Fezf1
Htt Lhx2
Olfr1383Olfr1384
Rac1
Reep1
Robo2
Rtp1
Rtp2
Slit1
Ttc8
Ubr3
Uncx
Centralization: 0.89
SRR2961069
Unsure
l
l
l
l
l
l
l
l
l
l
l
Agtpbp1
Chd7
Dmd
Htt
Id2
Lhx2
Olfr181
Rac1
Rpgrip1l
Rtp1
Uncx
Centralization: 0.89
SRR2911152
Immature l
l
ll
ll
Bcl11b
Dmd
Lhx2
Olfr1181
Rpgrip1l
Rtp1
Centralization: 0.9
SRR2911186
Immature
l
l
l
l
ll
Bbs1
Bcl11b
Eomes
Fezf1
Olfr1537
Olfr728
Centralization: 0.9
SRR2911195
Mature
l
l
l
l
l
l
l
l
ll
l l
l
l l
l l
l
l
Agtpbp1
Atf5
Bbs1
Bcl11b
Csf1r
Fezf1
Htt
Lhx2
Olfr725
Olfr726
Olfr727
Rac1
Reep1
Rtp1 Rtp2
Sema7a
Ski
Ttc8
Ubr3
Centralization: 0.9
SRR2961083
Mature
l
l
l
l
l
l
l
l
Agtpbp1
Atf5
Chd7
Id2
Lhx2
Olfr411
Olfr672
Robo2
Centralization: 0.9
SRR2911162
Immature l
l
l
l
l l
l
ll
l
Agtpbp1
Lhx2
Olfr222
Olfr390
Rpgrip1l
Rtp1
Rtp2
Slit1Ttc8
Ubr3
Centralization: 0.92
SRR2961104
Mature
l
l
l
l l
l
l
l
l
l
l
l l
l
Agtpbp1
Atf5
Axin1
Dicer1
Dmd
Eomes
Lhx2
Olfr1196
Reep1
Rpgrip1l
Rtp1
Rtp2 Sema7a
Ttc8
Centralization: 0.92
SRR2911226
Mature
l
l
l
l
l
l
l
Agtpbp1
Htt
Kif14
Pax6
Robo2
Rtp1
Uncx
Centralization: 0.93
SRR2961025
Unsure
l
ll
l l
l
ll
l
l
l
Agtpbp1
Atf5
Bbs1
Dicer1
Lhx2
Olfr309
Olfr420Rac1
Robo2
Rtp1
Rtp2
Centralization: 0.93
SRR2911114
Unsure
l
l
l
l
l
l
l
l
l
ll Agtpbp1
Atf5
Fezf1
Lhx2
Olfr114
Rac1
Reep1
Rtp1
Rtp2
Shank1
Uncx
Centralization: 0.93
SRR2911168
Unsure
Figure B.7: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
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Figure B.8: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
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Figure B.9: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
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Figure B.10: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
additional information for chapter 3 118
l
l
l
l
l l
l
l
l
l
l
Atf5
Bcl11b
Chd7
Dicer1
Eomes Lhx2
Olfr1006
Reep1
Rtp1
Rtp2
Ttc8
Centralization: 1
SRR2911171
Mature
l
l
l l
l
l
l
l l
l
Agtpbp1
Atf5
Bbs1 Id2
Olfr720
Reep1
Rtp1
Rtp2 Ubr3
Uncx
Centralization: 1
SRR2911179
Mature
l
l
l
l
l
l l
ll
l
Agtpbp1
Atf5
Csf1r
Lhx2
Olfr1143
Reep1 Robo2
Rtp1Sema7a
Uncx
Centralization: 1
SRR2911181
Mature
ll l
l
ll
l
l
l
l
ll
l
Agtpbp1
Atf5
Bcl11b
Htt
Lhx2
Olfr3
Rac1
Robo1
Rpgrip1l
Rtp1
Rtp2Ttc8
Ubr3
Centralization: 1
SRR2911185
Mature
l
l
l
l
l
l
l
l
Csf1r
Eomes
Olfr1348
Reep1
Rpgrip1l
Sema7a
Ubr3
Uncx
Centralization: 1
SRR2911193
Mature
l
l l
l
l
l
l l
l
l
l
Agtpbp1
Htt
Olfr77
Rac1
Robo2
Rpgrip1l
Rtp1
Rtp2
Slit1
Srf
Uncx
Centralization: 1
SRR2911198
Mature
l
l
l
l
l
l
l
l
l
l
l
l
Agtpbp1
Atf5
Bcl11b
Chd7
Htt
Lhx2
Olfr1263
Reep1
Rpgrip1l
Rtp1
Rtp2
Uncx
Centralization: 1
SRR2911202
Mature l
l
l
l l
l
l
l
l
Agtpbp1
Bbs1
Id2
Lhx2 Olfr1346
Reep1
Rpgrip1l
Rtp1
Uncx
Centralization: 1
SRR2911203
Mature
l
l
l
l
l
l
ll
l
ll
l
l
Agtpbp1
Atf5
Bbs1
Bcl11b
Csf1r
Lhx2
Olfr1484
Rac1
Rpgrip1l
Rtp1Sema7a
Ttc8
Ubr3
Centralization: 1
SRR2911204
Unsure
l
l
l
l
l
l
l
l
l
Atf5
Bbs1
Dicer1
Lhx2
Olfr921
Reep1
Rtp1
Rtp2
Ubr3
Centralization: 1
SRR2911205
Mature
l l
l l
l
l
l
l
ll
l
Atf5
Csf1r
Olfr1148
Pcnt
Rac1
Reep1
Robo2
Rpgrip1l
Rtp1Rtp2
Ubr3
Centralization: 1
SRR2911207
Mature
l
l
l
l
l
l
l
l
l
l
l
l
Agtpbp1
Atf5
Bbs1
Fezf1
Lhx2
Olfr743
Rac1
Rpgrip1l
Rtp2
Ski
Ttc8
Ubr3
Centralization: 1
SRR2911208
Mature
ll
l
l
l l
l
l l l
Agtpbp1
Atf5
Bbs1
Chd7
Olfr59 Reep1
Rpgrip1l
Rtp1 Sema7a
Ttc8
Centralization: 1
SRR2911209
Mature
l
l
l
l
l
l
l
l
l
l
l
l
Agtpbp1
Dicer1
Fezf1
Htt
Lhx2
Olfr353
Robo1
Rpgrip1l
Rtp1
Rtp2
Srf
Ubr3
Centralization: 1
SRR2911211
Mature
l
l
l
l
l
l
l
ll
l Agtpbp1
Atf5
Bbs1
Bcl11b
Eomes
Fezf1
Olfr17
Rtp2
Ski
Ttc8
Centralization: 1
SRR2911212
Mature
l
l
l
l
l
l
l
l
l
l
Agtpbp1
Atf5
Fezf1
Htt
Lhx2
Olfr1184
Robo2
Rtp1
Rtp2
Uncx
Centralization: 1
SRR2911214
Mature
l l
l
l
lDicer1 Olfr672
Reep1
Robo1
Rtp2
Centralization: 1
SRR2911215
Mature
ll
ll
l
ll
l
l
l
l
Agtpbp1
Atf5
Bbs1
Chd7
Csf1r
Olfr314
Rpgrip1l
Rtp1
Rtp2
Ttc8
Uncx
Centralization: 1
SRR2911216
Mature
l
l
l
l
l
l
l
l
l
l
Agtpbp1
Atf5
Dicer1
Ext1
Lhx2
Olfr1368
Reep1
Rpgrip1l
Rtp1
Rtp2
Centralization: 1
SRR2911217
Mature
l
l
l
l
l
l
Atf5
Csf1r
Eomes
Lhx2
Olfr827
Rtp1
Centralization: 1
SRR2911218
Mature
l
l
l
l
l
l
l
l
l
l
l
Atf5
Bbs1
Bcl11b
Dicer1
Htt
Lhx2
Olfr531
Rtp1
Rtp2
Ttc8
Uncx
Centralization: 1
SRR2911219
Immature
l
l
l
l
l
l
l
l
lAtf5
Chd7
Csf1r
Lhx2
Olfr517
Reep1
Rtp1
Ttc8
Uncx
Centralization: 1
SRR2911222
Mature l
l
l
l
ll
l
l
l
l
Atf5
Bbs1
Chd7
Dicer1
Fezf1
Olfr1255
Rpgrip1l
Rtp1
Rtp2
Ttc8
Centralization: 1
SRR2911223
Mature
ll l
l
l
Atf5Bbs1 Olfr374
Ttc8
Uncx
Centralization: 1
SRR2911224
Mature
Figure B.11: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
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Figure B.12: These graphs contain cell name (SRA or equivalent ID), visualisation of the
cell uniqueness network, its centralisation score as well as its classification
as a ‘mature’, ‘immature’ or ‘unsure’ of maturity cell, for all 211 non-trivial
cell networks.
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Table B.1: Candidate mature markers with known olfactory/neuronal expression and/or function.
Symbol Name Category Function Citation
Rtp1 Receptor transporter 1 Olfactory Related Transports olfactory receptors to cell sur-
face
(Saito et al., 2004)
Rtp2 Receptor transporter 2 Olfactory Related Transports olfactory receptors to cell sur-
face
(Saito et al., 2004)
Pdlim1 PDZ and LIM domain 1 Olfactory Related Differential zonal expression in the olfact-
ory epithelium
(Tietjen et al., 2005)
Nxph3 Neurexophilin 3 Olfactory Related Activated by cAMP in OSNs (Imai et al., 2006)
Ccdc114 Coiled-coil domain containing 114 Olfactory Related Ciliogenesis
Napa N-ethylmaleimide sensitive fusion
protein attachment protein alpha
Neural Processes Regulates SNARE complex (Söllner et al., 1993)
Cacna1h Calcium voltage gated subunit alpha
1H
Neural Processes Ca2+ voltage gated ion channel (Maue, 1987)
Car2 Carbonic anhydrase 2 Neural Processes Regulates neural excitation (Ruusuvuori et al., 2013;
Ruusuvuori and Kaila,
2014)
Arhgef28 Rho guanine nucleotide exchange
factor 28
Neural Processes Regulates axon growth and morphogen-
esis
(Mulinari and Häcker,
2010)
Boc Biregional cell adhesion molecule-
related/down-regulated by onco-
genes (Cdon) binding protein
Neural Processes Specifies neural circuits in cortex and
axon guidance candidate for commis-
sural axon growth
(Okada et al., 2006; Har-
well et al., 2012)
Sdc3 Syndecan 3 Neural Processes Influences neurite outgrowth and cell
spreading
(Toba et al., 2002; Bespa-
lov et al., 2011)
Tpm3 Tropomyosin 3, gamma Neural Processes Regulates neural polarity, and morpho-
genesis
(Dufour et al., 1998;
Schevzov, 2005)
Nfatc1 Nuclear factor of activated T cells,
cytoplasmic, calcineurin dependent 1
Neural Processes Regulates calcium signaling (Graef et al., 1999)
Ctsb Cathepsin B Neural Processes Important for maturation and integrity
of post natal CNS neurons
(Felbor et al., 2002)
Cend1 Cell cycle exit and neuronal differenti-
ation 1
Neural Processes Marks the termination of neuron-
generating divisions
(Politis et al., 2007)
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Table B.2: Candidate mature marker genes with unknown olfactory/neuronal expres-
sion and/or function.
Symbol Name
Map3k19 Mitogen-activated protein kinase kinase kinase 19
Slc16a11 Solute carrier family 16, member 11
Pck2 Phosphoenolpyruvate carboxykinase 2, mitochondrial
Selt Selenoprotein T
Tmem178b Transmembrane protein 178B
Vimp VCP-interacting membrane protein
Arxes2 Adipocyte-related X-chromosome expressed sequence 2
Atox1 Antioxidant 1 copper chaperone
Pgam1 Phosphoglycerate mutase 1
Ech1 Enoyl coenzyme A hydratase 1, peroxisomal
Rp2h Retinitis pigmentosa 2 homolog
Nwd1 NACHT and WD repeat domain containing 1
Rnf220 Ring finger protein 220
BC051077 BC051077
Gm11652 Predicted gene 11652
Gm12224 Predicted gene 12224
Gm12892 Predicted gene 12892
Gm14232 Predicted gene 14232
Gm14480 Predicted gene 14480
Gm26716 Predicted gene 26716
Gm5864 Predicted gene 5864
Gm6878 Predicted gene 6878
Gm867 Predicted gene 867
Tpm3-rs7 Tropomyosin 3, related sequence 7
Pgam1-ps2 Phosphoglycerate mutase 1, pseudogene 2
C
A D D I T I O N A L I N F O R M AT I O N F O R C H A P T E R 4
122
a
d
d
itio
n
a
l
in
fo
r
m
a
tio
n
fo
r
c
h
a
pter
4
123
Table C.1: The table describes the mutation data downloaded from TCGA. The dates and filenames for which the data was downloaded.
TCGA
Name
Date Mutation
info downloaded
Mutation Filename
BLCA 9 July 2015 broad.mit.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
BRCA 9 July 2015 genome.wustl.edu__IlluminaGA_curated_DNA_sequencing_level2.maf
COAD 10 June 2015 hgsc.bcm.edu__Illumina_Genome_Analyzer_DNA_Sequencing_level2.maf
GBM 30 June 2015 ucsc.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
HNSC 9 July 2015 broad.mit.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
KICH 9 July 2015 bcgsc.ca__IlluminaHiSeq_automated_DNA_sequencing_level2.maf
KIRC 9 July 2015 broad.mit.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
KIRP 9 July 2015 broad.mit.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
LAML 30 June 2015 genome.wustl.edu__Illumina_Genome_Analyzer_DNA_Sequencing_level2.maf
LGG 9 July 2015 broad.mit.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
LIHC 9 July 2015 broad.mit.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
LUAD 9 July 2015 broad.mit.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
LUSC 29 July 2014 broad.mit.edu__Illumina_Genome_Analyzer_DNA_Sequencing_level2.maf
OV 13 February 2014 broad.mit.edu__Illumina_Genome_Analyzer_DNA_Sequencing_level2.maf
PRAD 30 June 2015 broad.mit.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
READ 9 July 2015 hgsc.bcm.edu__Illumina_Genome_Analyzer_DNA_Sequencing_level2.maf
SKCM 14 November 2013 broad.mit.edu__Illumina_Genome_Analyzer_DNA_Sequencing_level2.maf
STAD 9 July 2015 hgsc.bcm.edu__IlluminaGA_automated_DNA_sequencing_level2.maf
UCEC 9 July 2015 genome.wustl.edu__Illumina_Genome_Analyzer_DNA_Sequencing_level2.maf
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Figure C.1: Comparison of PPI networks. The Venn diagrams show the overlap of
nodes (left) and edges (right) among the three PPI networks, UPPI, UPPI2
and HIPPIE network. UPPI and UPPI2 have the same number of nodes,
and the edges in UPPI are all within the edges in UPPI2.
Figure C.2: Distribution of mutations among all cancers. This graph shows the num-
ber of nonsilent mutations for each sample, ordered in increasing mutation
level of cancers. It is clear that in our dataset, there is a very high dynamic
range of mutations both within and between cancers, as well as varying
numbers of samples for each cancer.
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Figure C.3: The degree distribution of UPPI, generated by taking the union of five
PPI networks and the HIPPIE network. The genes above a degree of 250
are highlighted and labelled. For UPPI there are 17 such genes and for
HIPPIE there are 12 such genes.
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Figure C.4: Methods overview for pathway-based approach. A binary matrix of nonsi-
lent mutations are filtered based on a minimum percentage mutation rate,
and connectedness in the UPPI network. Among random subsets of the
samples, linear models are fitted using these binary vectors to test for dif-
ferential gene set expression among the pathways in the KEGG database.
Then directed edges are drawn among repeatedly mutated genes and the
significantly differentially expressed pathways.
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Figure C.5: Enrichment of generated networks. The heatmap displays comparisons of
the non-empty networks generated for each cancer against networks gen-
erated through randomly permuting the sample and gene labels. The top
heatmap is for the HIPPIE network and bottom is for UPPI. Cancers are
ordered in increasing overall mutation rate. Enrichment of genes among
the NCG 4.0 (An et al., 2014), CGC (Futreal et al., 2004) and DrugBank
(Law et al., 2014) databases, as well as the driver nodes identified through
DriverNet algorithm are displayed, using all nodes in the directed network,
the tail nodes and head nodes respectively. Cell colours correspond to em-
pirical p-values, blue closer to 1 and white closer to 0, with empirical p-
values less than 0.1 enumerated.
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Figure C.6: A bipartite graph generated in the SKCM dataset by testing for differen-
tial gene set expression via mutations in the genes along the left side, with
edges drawn between significant pairs. The graph was filtered for clarity
by removing large and highly connected KEGG pathways of 50 or more
genes and removing pairs in which no other edges are drawn.
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Unmatched analysis: Patient clinical information and gene expression data
Metastatic melanoma
We used the publicly available data from Mann et al. (2013) (GEO Accession Number:
GSE59334) describing gene expression microarray profiling in American Joint Commit-
tee on Cancer (AJCC) stage III (Balch et al., 2009) melanoma (Table C.2). After filtering
and processing as previously described (Mann et al., 2013), the data set comprised ex-
pression data for 17,552 genes for each of 47 patients. Survival times were previously
analysed (Mann et al., 2013) and we used these same groups in our analysis: patients
having time from surgery for resection of nodal metastatic disease to death from melan-
oma >4 years with no sign of relapse (nMELGEO_GoodPrognosis = 25) or <1 year due
to melanoma (nMELGEO_PoorPrognosis = 22) (Figure C.7A).
We analysed an additional and independent metastatic melanoma dataset in the Skin
Cutaneous Melanoma (TCGA identifier: SKCM) samples from TCGA (downloaded on
23/06/2013) (Table C.2). Patient stage at time of analysis was only available for the
subset of samples from the tissue source site (TSS) ‘EE’ (Melanoma Institute Australia,
North Sydney, Australia). Trimmed mean of M-values (TMM) (Robinson and Oshlack,
2010) normalised RNA-Seq expression data were used and filtered based on a min-
imum threshold, so that the mean normalised RNA-Seq counts were above 20. Ana-
lysis using the survival criteria mentioned above was not possible due to ineffectual
sample size. To maximize power we therefore compared patients having time from sur-
gery after resection of nodal metastatic disease to death from melanoma >3 years with
no sign of relapse (nMELTCGA_GoodPrognosis = 11) and patients surviving <2 years
after same (nMELTCGA_PoorPrognosis = 12) (Figure C.7B). The final analysis matrix
contained expression data for 15,409 genes for each of the 23 patients.
We also considered the sensitivity of the approach by analysing an alternate survival
threshold: patients having time from surgery to death from melanoma >4 years with
no sign of relapse and 64 years after same (Table C.2).
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Lung squamous cell carcinoma
Data (TCGA identifier: LUSC) were downloaded from TCGA on 29/07/2014. All
primary LUSC tumour tissue samples (identified as samples with TCGA barcodes
‘TCGA-XX-XXXX-01’) were included. We selected late stage patients, with either stage
III or IV under ‘ajcc_pathologic_tumor_stage’ (Table C.2). TCGA normalised RNA-Seq
count data were used with genes filtered based on a minimum threshold expression
level of >20 normalised read counts over all samples. The data contained expression
data for 18,023 genes for each of 26 patients. Based on relevance to the clinic as well
as the number of samples available in each class, we defined longer and shorter pa-
tient survival groups as survival >4 years (nLUSC_LongerSurvival = 14) and <3 years
(nLUSC_ShorterSurvival = 12), respectively (Figure C.7C).
Serous ovarian carcinoma
Normalised gene expression microarray data from a series of both high and low-grade
serous ovarian cancers were downloaded via the curatedOvarianData R package (Gan-
zfried et al., 2013) (version 1.2.0) corresponding to the data set of Tothill et al. (2008)
(Table C.2). Based on relevance to the clinic as well as the number of samples available
in each class, we defined longer and shorter patient survival groups as survival >3
years (ncuratedOvarianData_LongerSurvival = 89) and
<1 year (ncuratedOvarianData_ShorterSurvival = 18), respectively. The final analysis
set comprised expression data for 17,934 genes for each of 107 patients (Figure C.7D).
Independent data for Ovarian serous cystadenocarcinoma (TCGA identifier: OV)
were downloaded from TCGA on 06/05/2014 (Table C.2). We analysed all primary
tumour tissue samples (identified as samples with TCGA barcodes ‘TCGA-XX-XXXX-
01’) and selected advanced-stage, high-grade serous ovarian samples (either IIIA, IIIB,
IIIC, or IV) under the variable ‘clinical_stage’. TCGA normalised RNA-Seq count data
were used with genes filtered based on a minimum threshold expression level of >20
normalised read counts over all samples. The expression data set comprised expres-
sion data for 18,963 genes in each of 100 patients. We used the survival groups defined
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above such that nOVpatients_LongerSurvival = 86 and
nOVpatients_ShorterSurvival = 14) (Figure C.7E).
Lung adenocarcinoma
Data (TCGA identifier: LUAD) were downloaded from TCGA on 09/07/2015 (Table
C.2). We analysed all primary tumour tissue samples (identified as samples with
TCGA barcodes ‘TCGA-XX-XXXX-01’). TCGA normalised RNA-Seq count data were
used with genes filtered based on a minimum threshold expression level of 20 nor-
malised read counts over all samples. The data contain expression information for
19,292 genes for each of 267 patients. After examining various inclusion/exclusion
criteria as well as different survival endpoint thresholds (see next paragraph for de-
tails), we defined longer and shorter patient survival groups as survival >2 years
(nLUAD_LongerSurvival = 219) and <1.5 years (nLUAD_ShorterSurvival = 48), respect-
ively (Figure C.7F).
To examine the utility of our approach in later stage disease we considered two
additional analyses using the same data above. We first restricted the cohort to ana-
lysis of only late stage samples (either IIIA, IIIB, or IV) using the clinical variable
‘ajcc_pathologic_tumor_stage’. We then analysed: 1) patients having time from dia-
gnosis to death >3 years versus <2 years; and, 2) patients having time from diagnosis
to death >2 years versus <1.5 years (Table C.2).
Mutation information
Somatic mutation data for each cancer analysed were downloaded from TCGA (Table
C.2). We used MutSigCV v1.3 (Lawrence et al., 2013) as a way to assess the evidence
for the gene being a driver gene for that particular disease, using default parameters
and provided mutation dictionary, coverage, and gene covariates files. The negative
log of the q-value (false discovery rate (FDR)-adjusted p-value) from MutSigCV was
the estimate of driver gene score (DGS) we used. A low FDR-adjusted q-value from
MutSigCV suggested the gene has a driving role in disease development and/or pro-
gression. In this way, taking the score as the negative log transformation of the FDR-
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adjusted q-value corresponded to a higher score pointing to possible driver genes.
Since for the majority of genes the q-values were close to 1, the DGS score was close to
zero for many genes.
Protein-protein interaction (PPI) networks
We analysed five PPI networks (Table 4.2), four of which were previously prepared
(Schramm et al., 2013a) from the following sources: MetaCore (from GeneGO Inc., ver-
sion 6.6, build 28323), iRefWeb (V3.4, March 2, 2011) (Turner et al., 2010), HPRD (Ke-
shava Prasad et al., 2009) and BioGRID (Breitkreutz et al., 2007). In addition, we used the
recently published PPI data from the Human Interactome (HI) Project (Rolland et al.,
2014) in which binary PPIs were identified using a primary yeast two-hybrid assay
(Y2H) followed by orthogonal validation via alternative binary assay. The MetaCore
network contains 5,009 genes and has 16,202 edges. The iRefWeb network comprises
7,256 genes and has 21,049 edges. The HPRD network contains 9,453 genes and has
36,867 edges. The BioGRID network contains 4,094 genes and 8,097 edges. The HI net-
work contains 4,303 genes and 13,427 edges. Consistent with prior literature (Schramm
et al., 2013a; Taylor et al., 2009), we defined a hub protein to be one with a protein in-
teraction partner degree greater than or equal to five. A hub subnetwork was therefore
defined as a hub and its directly binding protein interaction partners.
Computational prediction of patient outcome-related disturbances in PPI networks
For all cohorts considered, a multi-stage statistical approach was used to test for as-
sociations between prognosis-related PPI network gene correlation disturbances and
DGS (Figure 4.9). First we implemented the method of (Taylor et al., 2009) to gene ex-
pression information to identify hub subnetworks in association with patient survival
classes. This was implemented using functions from the R package VAN for identify-
ing biologically perturbed networks via differential variability analysis (Jayaswal et al.,
2013). For this particular analysis, five separate lists of significant hub subnetworks
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were generated, corresponding to each PPI network. Since each PPI network contained
a different set of nodes and edges, these lists were combined via Fisher’s method of
meta-analysis (Figure 4.9), ignoring PPIs for which a particular hub did not meet the
criteria to be included. This approach accommodated that according to our definition
of a hub subnetwork, a particular node may not necessarily be called a ‘hub’ node
for all PPI networks, that is may not necessarily have at least five interactors. Next,
for each cancer, we used a bootstrap test to identify hubs with interaction partners
having a higher mean DGS than would be expected by chance (Schramm et al., 2013a).
This also generated five sets of significant hub sub-networks for each PPI. We deemed
a hub subnetwork to be significant if it appeared two or more times out of the five
sets of significant (p-value<0.05) hub subnetworks. Last, we used Fisher’s exact test to
evaluate whether these mutation-associated networks were significantly (p-value<0.05)
overrepresented relative to equivalent sets. We ensured that hubs that could not be
significant for either test due to a lack of measurement in any of the three data sources
(gene expression, mutation or PPI) were excluded.
Patient outcome-related PPI networks are significantly disturbed in association with mutation
in four cancers
Metastatic melanoma
Using the in-house metastatic melanoma data (Mann et al., 2013) we identified 15 sig-
nificantly (p-value<0.05) disturbed PPI networks in association with 4 mutated inter-
action partners (DGS>0): CDKN2A, BRAF, PTEN, and TP53. All of these genes had
prior causal associations to cancer, and two of them (BRAF and TP53) were existing
drug targets. In TCGA:SKCM data we identified 48 disturbed networks (p-value<1e−5)
corresponding to the 4 mutated genes mentioned above as well as B2M, NDUFB9, and
NF1. Most of these genes had been previously causally associated with cancer (exclud-
ing B2M and NDUFB9). In addition to BRAF and TP53, B2M was already a known
drug target.
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Lung squamous cell carcinoma (LUSC)
In TCGA:LUSC data we identified 42 significantly disturbed networks (p-value<0.01)
in relation to 6 mutated interaction partners (DGS>0): CDKN2A, NFE2L2, PTEN, KEAP1,
RB1, and TP53. The latter three genes were identified in DrugBank as existing targets
while all of them except KEAP1 had previous reports of causal association with cancer.
Serous ovarian carcinoma (OV)
Our analysis of TCGA:OV data pointed to TP53 (DGS>0) as a functionally mutated
partner of 34 (p-value<1e−5) survival-associated PPI networks. Per the melanoma data,
downstream analyses identified TP53 as both an existing drug target and a causal
associate of multiple cancers.
Lung adenocarcinoma (LUAD)
In TCGA:LUAD we observed 50 (p-value<0.01) significant network disturbances in
association with 21 interaction partner mutations (DGS>0): ARID1A, ATM, BRAF, BTK,
CD4, CDKN2A, CTNNB1, DAP3, EGFR, GRB2, KCTD6, KEAP1, KRAS, MAF1, MUC7,
RB1, RIT1, S100A6, SMARCA4, STK11, and TP53. The known drug targets in this list
were ATM, BRAF, CD4, EGFR, GRB2, KEAP1, RB1, and TP53. Causal associations with
any cancer were previously observed for ARID1A, ATM, BRAF, CDKN2A, CTNNB1,
EGFR, KRAS, RB1, SMARCA4, STK11, and TP53.
additional information for chapter 4 135
Figure C.7: Cohort survival cut points. Survival thresholds were chosen on the basis
of clinical relevance according to the literature with consideration also
given to sample size in terms of statistical power. A: Cutaneous meta-
static melanoma, American Joint Committee on Cancer (AJCC) stage III
(Jayawardana et al., 2015; Mann et al., 2013); B: TCGA Skin Cutaneous
Melanoma (SKCM), AJCC stage III (Akbani et al., 2015); C: TCGA Lung
Squamous Cell Carcinoma (LUSC), AJCC pathologic tumour stages III and
IV (Hammerman et al., 2012); D: Serous ovarian carcinoma (curatedOvari-
anData), high and low grade (Ganzfried et al., 2013; Tothill et al., 2008); E:
TCGA Ovarian Carcinoma (OV), high grade (clinical stages III and IV) (Bell
et al., 2011); F: TCGA Lung adenocarcinoma (LUAD), all primary tumour
tissue samples (Collisson et al., 2014).
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Table C.2: Summary of cancer data analysed and results. For each cancer analysed, we capture the sources of data analysed (including date
of download), cohort inclusions and exclusions, sample sizes, significance value for the relationship between hub subnetwork
and driver gene score, and the number of significant (p-value<0.05) hub subnetworks.
Cancer Transcriptome datasource (platform)
Mutation data source
(platform: sample size)
Date of
download
Cohort inclu-
sions Survival classes compared
Class sizes
(good:poor) FET P-value Number
Skin
cutaneous
melanoma
(Mann et al., 2013) GEO:
GSE59334 (Illumina
Sentrix Human-6 v3
Expression BeadChips)
TCGA: SKCM (Illu-
mina Genome Analyzer
DNA-Seq: 344)
23/06/2013
AJCC stage
III metastatic
melanoma
Time from surgery to death
from melanoma >4yr with no
sign of relapse and <1yr as
‘poor’ for the same.
25:22 <0.05 15
TCGA: SKCM (Illumina
HiSeq RNA-Seq)
AJCC stage
III metastatic
melanoma, EE
TSS samples
Time from surgery to death
from melanoma >3yr with no
sign of relapse and <2yr as
‘poor’ for the same.
11:12 <1E-6 48
AJCC stage
III metastatic
melanoma, EE
TSS samples
Time from surgery to death
from melanoma greater than 4
years with no sign of relapse
and equal to/less than four
years after same
16:12 <0.20 25
Lung
squamous
cell
carcinoma
TCGA: LUSC (Illumina
HiSeq RNA-Seq)
TCGA: LUSC (Illumina
Genome Analyzer
DNA-Seq: 178)
29/07/2014
AJCC pathologic
tumor stage III
and IV
Time from diagnosis to death
>4yr were defined as ‘good’ and
<3yr as ‘poor’ for the same.
14:12 <0.001 42
Serous
Ovarian
Carcinoma
TCGA: OV (Illumina
HiSeq RNA-Seq)
TCGA: OV (Illumina
Genome Analyzer
DNA-Seq: 142)
6/05/2014
High-grade
primary tumors
with clinical
stage III and IV
Time from diagnosis to death
>3yr were defined as ‘good’ and
<1yr as ‘poor’ for the same.
86:14 <1E-8 34
curatedOvarianData
(Ganzfried et al., 2013;
Tothill et al., 2008)
GEO: GSE9891 (HG-
U133_Plus_2 Affymet-
rix Human Genome
U133 Plus 2.0 Array)
30/09/2014
All primary
tumours with
early and late
stage, and low-
and high-grade
Time from diagnosis to death
>3yr were defined as ‘good’ and
<1yr as ‘poor’ for the same.
75:18 0.18 26
Lung
adenocar-
cinoma
TCGA: LUAD (Illumina
HiSeq RNA-Seq)
TCGA: LUAD (Illu-
mina Genome Analyzer
DNA-Seq: 519)
9/07/2015 All primary tu-mors
Time from diagnosis to death
>2yr were defined as ‘good’ and
<1.5yr as ‘poor’ for the same.
219:48 <0.002 50
AJCC pathologic
tumor stage III
and IV
Time from diagnosis to death
>3yr were defined as ‘good’ and
<2yr as ‘poor’ for the same.
14:19 0.7 33
Time from diagnosis to death
>2yr were defined as ‘good’ and
<1.5yr as ‘poor’ for the same.
25:16 0.16 32
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Table C.3: Cutaneous metastatic melanoma (SKCM): Summary of future research directions. We undertook a systematic literature review of
all mutated interaction partners from significantly disturbed hub subnetworks. The output was collated and used to categorise
genes according to future research directions.
Interactor COSMIC DRUGBANK Direction of future investigation
BRAF X X Current therapeutic target and prognostic biomarker (Akbani et al., 2015; Mann et al., 2013)
TP53 X X Investigational therapeutic target (Box et al., 2014)
CDKN2A X Investigational therapeutic target (Akbani et al., 2015)
PTEN X Potential clinical relevance (Akbani et al., 2015)
NF1 X Potential clinical relevance (Akbani et al., 2015; Hodis et al., 2012)
B2M X Drug repurposing, predictive biomarker (Sucker et al., 2014)
NDUFB9 Biologic relevance to melanoma, putative target or biomarker (Li et al., 2015b)
Table C.4: High-grade serous ovarian cancer (OV): Summary of future research directions. We undertook a systematic literature review of
all mutated interaction partners from significantly disturbed hub subnetworks. The output was collated and used to categorise
genes according to future research directions.
Interactor COSMIC DRUGBANK Direction of future investigation
TP53 X X Investigational therapeutic target, prognostic biomarker (Ahmed et al., 2010; Ross et al., 2013;
Bell et al., 2011; Vang et al., 2009)
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Table C.5: Lung adenocarcinoma (LUAD): Summary of future research directions. We undertook a systematic literature review of all
mutated interaction partners from significantly disturbed hub subnetworks. The output was collated and used to categorise
genes according to future research directions.
Interactor COSMIC DRUGBANK Direction of future investigation
ATM X X Investigational therapeutic target, prognostic biomarker (Weber and Ryan, 2015)
BRAF X X Investigational therapeutic target (Collisson et al., 2014)
EGFR X X Current therapeutic target and prognostic biomarker (Oser et al., 2015; Collisson et al., 2014)
RB1 X X Investigational predictive biomarker (Knudsen and Wang, 2010; Swanton and Govindan, 2016;
Collisson et al., 2014)
TP53 X X Investigational therapeutic target, prognostic biomarker (Ding et al., 2008; Gibbons et al., 2014;
Collisson et al., 2014)
ARID1A X Investigational therapeutic target ((Collisson et al., 2014))
CDKN2A X Investigational therapeutic target (Collisson et al., 2014)
CTNNB1 X Investigational therapeutic target (Collisson et al., 2014)
KRAS X Investigational therapeutic target (Collisson et al., 2014)
SMARCA4 X Investigational therapeutic target (Collisson et al., 2014)
STK11 X Investigational therapeutic target (Collisson et al., 2014)
CD4 X Drug repurposing (Lu et al., 2015)
GRB2 X Drug repurposing, prognostic biomarker (Timsah et al., 2015; Xu, 2011)
KEAP1 X Drug repurposing (Booth et al., 2016; Collisson et al., 2014)
BTK Biologic relevance to LUAD, putative target or biomarker (Sagiv-Barfi et al., 2015)
DAP3 Biologic relevance to LUAD, putative target or biomarker (Woo Lee et al., 2006)
KCTD6 Biologic relevance to LUAD, putative target or biomarker
MAF1 Biologic relevance to LUAD, putative target or biomarker (Palian et al., 2014)
MUC7 Biologic relevance to LUAD, putative target or biomarker (Lakshmanan et al., 2015)
RIT1 Biologic relevance to LUAD, putative target or biomarker (Collisson et al., 2014)
S100A6 Biologic relevance to LUAD, putative target or biomarker (De Petris et al., 2009; Wang et al.,
2010)
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Table C.6: Lung squamous cell carcinoma (LUSC): Summary of future research directions. We undertook a systematic literature review of
all mutated interaction partners from significantly disturbed hub subnetworks. The output was collated and used to categorise
genes according to future research directions.
Interactor COSMIC DRUGBANK Direction of future investigation
TP53 X X Investigational therapeutic target, prognostic biomarker (Gibbons et al., 2014; Hammerman
et al., 2012)
RB1 X X Investigational predictive biomarker (Knudsen and Wang, 2010; Swanton and Govindan, 2016;
Hammerman et al., 2012)
CDKN2A X Potential clinical relevance (Hammerman et al., 2012)
PTEN X Potential clinical relevance (Hammerman et al., 2012)
NFE2L2 X Potential clinical relevance, prognostic biomarker (Hammerman et al., 2012) (Shibata et al.,
2008)
KEAP1 Drug repurposing (Shibata et al., 2008; Hammerman et al., 2012)
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